<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey W Clark, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hanna K Sanoff, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard M Goldberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of metastatic colorectal cancer (mCRC) is evolving. In addition to chemotherapy, many active agents for mCRC have been developed that are associated with improved overall survival. Management is also increasingly being driven by tumor biology and gene expression analysis of individual tumors. (See
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'Predictive biomarkers'
         </a>
         .)
        </p>
        <p>
         The approach to initial systemic therapy for patients with inoperable mCRC is discussed here. General principles of chemotherapy treatment for mCRC (including the role of maintenance therapy), approach to later lines of systemic therapy for inoperable metastatic CRC, recommendations for systemic chemotherapy in older adult patients with mCRC, the integration of chemotherapy with surgery for patients with potentially resectable liver metastases, and a compilation of chemotherapy regimens used for advanced CRC are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2512.html" rel="external">
          "Therapy for metastatic colorectal cancer in older adult patients and those with a poor performance status"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/85679.html" rel="external">
          "Treatment protocols for small and large bowel cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4256214653">
         <span class="h1">
          OVERVIEW OF THE THERAPEUTIC APPROACH
         </span>
        </p>
        <p class="headingAnchor" id="H2860149477">
         <span class="h2">
          Available agents and strategy for selection of the approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are now several classes of drugs that are available for first-line therapy of mCRC:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluoropyrimidines (including
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         [FU], which is usually given intravenously with
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         [LV], and the oral agents
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         , S-1, and tegafur plus uracil [UFT]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          Irinotecan
         </a>
         , which is active as monotherapy as well as in combination with other active agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          Oxaliplatin
         </a>
         , which is only active when partnered with a second cytotoxic agent, most commonly a fluoropyrimidine.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          Cetuximab
         </a>
         and
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         , two monoclonal antibodies (MoAbs) directed against the epidermal growth factor receptor (EGFR).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          Bevacizumab
         </a>
         , a MoAb targeting the vascular endothelial growth factor (VEGF).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunotherapy with an immune checkpoint inhibitor that targets the programmed death receptor 1 (PD-1; ie, the MoAb
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         ). (See
         <a class="local">
          'Patients with deficient DNA mismatch repair/microsatellite unstable tumors'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HER2-targeted agents may be useful for selected patients with HER2-overexpressing tumors, although these agents are more commonly used for later lines of therapy and this is not our preferred approach.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1069158911">
         <span class="h2">
          Predictive biomarkers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increasingly, biomarker expression is driving therapeutic decision-making in oncology, including mCRC. Gene profiling of tumor tissue (ie, with next-generation sequencing) should be undertaken as quickly as possible after a diagnosis of metastatic colorectal cancer. (See
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'Predictive biomarkers'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Benefit from MoAbs targeting the EGFR is restricted to patients whose tumors do not contain mutated
         <em>
          RAS
         </em>
         genes. Furthermore, evidence increasingly suggests that response to EGFR-targeted agents either alone or in combination with chemotherapy is unlikely in patients whose tumors harbor a
         <em>
          BRAF
         </em>
         V600E mutation, although EGFR inhibitors have shown activity in combination with a
         <em>
          BRAF
         </em>
         inhibitor [
         <a href="#rid1">
          1
         </a>
         ]. Emerging data also suggest that the location of the primary tumor is another factor that influences the efficacy of EGFR inhibitors. (See
         <a class="local">
          'RAS/BRAF wild-type tumors'
         </a>
         below and
         <a class="local">
          'EGFR inhibitors versus bevacizumab and the influence of tumor sidedness'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'Impact of RAS status on the use of EGFR inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Benefit from immunotherapy with a PD-1 inhibitor appears to be limited to the subset of tumors with high levels of microsatellite instability (MSI-H)/deficient mismatch repair (dMMR) or, in the second-line setting and beyond, high levels of tumor mutational burden. (See
         <a class="local">
          'Patients with deficient DNA mismatch repair/microsatellite unstable tumors'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Microsatellite unstable/deficient mismatch repair tumors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'dMMR or MSI-H tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although more commonly used for later lines of therapy, some patients with HER2-overexpressing mCRC may be eligible for first-line therapies targeting HER2. (See
         <a class="local">
          'Not candidates for intensive therapy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'RAS wild-type, HER2 overexpressors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For most patients, treatment will be palliative and not curative, and the treatment goals are to prolong overall survival (OS) and maintain quality of life (QOL) for as long as possible. (See
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'Treatment goals'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         However, some patients with stage IV disease (particularly those with liver- or lung-limited metastases) can be surgically cured of their disease. Even selected patients with initially unresectable liver metastases may become eligible for resection if the response to chemotherapy is sufficient, although this is uncommon. This approach has been termed "conversion therapy" to distinguish it from neoadjuvant therapy that is given to patients who present upfront with apparently resectable disease. The key parameter for selecting the specific regimen in this scenario is not survival or improved QOL, but instead, response rate (ie, the ability of the regimen to shrink metastases). (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Patients with initially unresectable metastases'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2667425267">
         <span class="h2">
          Initial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We select initial therapy for patients with nonoperable disease based upon patient fitness and comorbidity,
         <em>
          RAS
         </em>
         and
         <em>
          BRAF
         </em>
         mutation status, the presence of dMMR/MSI-H, the location of the primary tumor, and the intent of therapy. An algorithmic approach to selecting initial therapy based upon these factors is presented in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef109247" href="/z/d/graphic/109247.html" rel="external">
          algorithm 1
         </a>
         ), and the data supporting this approach are discussed below.
        </p>
        <p>
         The optimal duration of initial chemotherapy for categorically unresectable disease in the absence of disease progression is debated. In general, the decision to permit treatment breaks during initial therapy (ie, intermittent rather than continuous therapy) must be individualized and based upon several factors, including tolerance of and response to chemotherapy, disease bulk and location, and symptomatology. (See
         <a class="local">
          'Duration of initial chemotherapy'
         </a>
         below.)
        </p>
        <p>
         The optimal duration of chemotherapy for patients who have initially unresectable metastases, but that responds to treatment such that their disease becomes potentially resectable, is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Patients with initially unresectable metastases'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2060049921">
         <span class="h2">
          Subsequent treatment and the continuum of care model
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to subsequent therapy is variable and might include maintenance chemotherapy (particularly for patients treated initially with an oxaliplatin-containing regimen) or a switch to a different regimen altogether because of disease progression or intolerance to the initial regimen. (See
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'Continuous versus intermittent therapy'
         </a>
         .)
        </p>
        <p>
         For patients with mCRC, the model of distinct "lines" of chemotherapy (in which regimens containing non-cross-resistant drugs are each used in succession until disease progression) is being abandoned in favor of a "continuum of care" approach [
         <a href="#rid2">
          2
         </a>
         ]. This approach emphasizes an individualized treatment strategy that might include phases of maintenance chemotherapy interspersed with more aggressive treatment protocols, rechallenging patients who responded to first-line treatment with the same agents used first-line [
         <a href="#rid3">
          3-6
         </a>
         ], treatment-free intervals, as well as reutilization of previously administered chemotherapy agents in combination with other active drugs.
        </p>
        <p>
         An important principle is that exposure to all active drugs during the course of treatment for mCRC, as appropriate, is more important than the specific sequence of drug administration in order to maximize OS. The proportion of patients receiving all active agents correlates strongly with median survival in all large published phase III trials over the last decade [
         <a href="#rid2">
          2,7,8
         </a>
         ]. Our general approach to treatment at progression after the first-line regimen is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Options for treatment at progression'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1008410279">
         <span class="h2">
          Resource-constrained settings
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach outlined above assumes that health care resources are not a limiting factor to selecting treatment. There are few data to guide the treatment strategy for mCRC in resource-constrained settings. The American Society of Clinical Oncology (ASCO) has developed consensus-based guidelines for treatment of late-stage colorectal cancer that stratify recommendations based on the available level of services (basic, limited, enhanced, and maximal  (
         <a class="graphic graphic_table graphicRef120538" href="/z/d/graphic/120538.html" rel="external">
          table 1
         </a>
         )) [
         <a href="#rid9">
          9
         </a>
         ]. They include specific recommendations for initial diagnostic evaluation, systemic therapy in the first-line setting and beyond, and surgical management of patients with potentially resectable disease.
        </p>
        <p class="headingAnchor" id="H554565932">
         <span class="h1">
          PATIENTS WITH PROFICIENT DNA MISMATCH REPAIR/MICROSATELLITE STABLE TUMORS
         </span>
        </p>
        <p class="headingAnchor" id="H2791386770">
         <span class="h2">
          Candidates for intensive systemic therapy
         </span>
        </p>
        <p class="headingAnchor" id="H553389076">
         <span class="h3">
          The cytotoxic chemotherapy backbone
         </span>
        </p>
        <p class="headingAnchor" id="H1000698550">
         <span class="h4">
          Three- versus two-drug combinations
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with a good performance status who are able to tolerate intensive therapy, particularly those with a high tumor burden and those who need conversion therapy for initially unresectable but potentially resectable liver metastases we suggest an initial course of three to six months of triplet therapy with FOLFOXIRI (
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         and
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         with
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         [FU]/
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         [LV]), rather than an initial chemotherapy doublet (ie, oxaliplatin plus LV and short-term infusional FU [FOLFOX],
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         plus oxaliplatin [CAPOX, XELOX], or irinotecan plus LV and short-term infusional FU [FOLFIRI]) for first-line chemotherapy. For other patients with mCRC and a good performance status, we suggest a balanced discussion of values and preferences to decide whether the added toxicity of triplet therapy is worth the relatively small incremental improvement in survival as compared with a chemotherapy doublet containing either oxaliplatin or irinotecan. This recommendation is consistent with consensus-based guidelines from the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and a year 2022 guideline on management of mCRC from the American Society of Clinical Oncology (ASCO) [
         <a href="#rid10">
          10-12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2484.html" rel="external">
          "Pathology and prognostic determinants of colorectal cancer", section on 'RAS and BRAF'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/85679.html" rel="external">
          "Treatment protocols for small and large bowel cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Patients with initially unresectable metastases'
         </a>
         .)
        </p>
        <p>
         Compared with doublet regimens that contain either
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         or
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         , high rates of objective response and favorable long-term disease-free and overall survival (OS) rates have been reported in most (but not all) trials of regimens that combine FU and LV plus both irinotecan and oxaliplatin (such as the FOLFOXIRI  (
         <a class="graphic graphic_table graphicRef70559" href="/z/d/graphic/70559.html" rel="external">
          table 2
         </a>
         ) regimen), with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         or
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         [
         <a href="#rid13">
          13-28
         </a>
         ].
        </p>
        <p>
         The following reflects the range of findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          FOLFOXIRI versus FOLFIRI
         </strong>
         – Two phase III trials comparing FOLFOXIRI versus the Douillard
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         /FU/LV (which is less dose-intensive than FOLFIRI) regimen  (
         <a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">
          table 3
         </a>
         ) have come to opposite conclusions about the benefit of triplet therapy [
         <a href="#rid18">
          18-21
         </a>
         ], while a third phase III trial comparing FOLFOXIRI plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         versus FOLFIRI plus bevacizumab suggests superiority for FOLFOXIRI in terms of response rate and progression-free survival (PFS) but comparable rates of subsequent complete resection of liver metastases [
         <a href="#rid17">
          17
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In an Italian trial that randomly assigned 244 patients with previously untreated inoperable mCRC to the Douillard FU plus
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         regimen versus FOLFOXIRI, FOLFOXIRI was significantly superior in terms of response rate (the primary endpoint, 66 versus 41 percent), the number of patients able to undergo complete secondary surgical cytoreduction of liver metastases (15 versus 6 percent), median PFS, and median OS (23 versus 17 months) [
         <a href="#rid18">
          18,19
         </a>
         ]. These benefits came at a cost of treatment-related neuropathy with FOLFOXIRI (19 percent grade 2 or 3), and higher rates of grade 3 or 4 neutropenia (50 versus 28 percent) with triplet therapy [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Similar high rates of objective response and significantly better median OS (29.8 versus 25.8 months) were noted with FOLFOXIRI plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         (
         <a class="graphic graphic_table graphicRef127023" href="/z/d/graphic/127023.html" rel="external">
          table 4
         </a>
         ) as compared with FOLFIRI plus bevacizumab in the TRIBE trial, but it did not confirm the higher rates of secondary surgical resection of liver metastases with an initial three-drug chemotherapy backbone (15 versus 12 percent with FOLFIRI) [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A benefit for initial FOLFOXIRI as compared with a preplanned sequential strategy of exposure to the same agents in two subsequent lines of therapy was shown in a later trial by this same group (the TRIBE2 trial) [
         <a href="#rid20">
          20
         </a>
         ]. The benefits of upfront FOLFOXIRI/
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         included a significantly greater time to second disease progression, a greater objective response rate, and longer OS (27.4 versus 22.5 months). These benefits came at the cost of significantly more grade 3 or 4 diarrhea, neutropenia, and febrile neutropenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In contrast to these two trials, a Hellenic Oncology Research Group (HORG) trial of 283 patients with previously untreated mCRC noted no significant benefit for FOLFOXIRI over the Douillard regimen of FU/LV/
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         (
         <a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">
          table 3
         </a>
         ) in terms of median OS (21.5 versus 19.5 months), time to tumor progression (8.4 versus 6.9 months), or objective response rate (43 versus 34 percent) [
         <a href="#rid21">
          21
         </a>
         ]. However, the FOLFOXIRI regimen used in this trial contained smaller doses of irinotecan,
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         , and FU.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          FOLFOXIRI versus FOLFOX
         </strong>
         – Additional data supporting the benefit of initial triplet therapy come from trials comparing FOLFOXIRI versus FOLFOX, with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         [
         <a href="#rid22">
          22,23,26
         </a>
         ]. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The phase III STEAM trial randomly assigned 280 patients with previously untreated mCRC to
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         plus FOLFOX, concurrent FOLFOXIRI, or sequential FOLFOXIRI, which consisted of alternating courses of FOLFOX and FOLFIRI every four weeks [
         <a href="#rid22">
          22
         </a>
         ]. The objective response rates were higher for concurrent FOLFOXIRI/bevacizumab (73 versus 62 percent for FOLFOX/bevacizumab), median PFS was modestly but significantly better (11.7 versus 9.5 months, hazard ratio [HR] 0.7, 95% CI 0.5-0.9), and almost twice as many patients were able to undergo secondary liver resection (17.2 versus 9.8 percent). Results did not differ significantly for sequential administration of alternating FOLFOX and FOLFIRI compared with concurrent FOLFOXIRI.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The phase III VISNU-1 trial randomly assigned 349 patients younger than age 70 with three or more circulating tumor cells (a poor prognostic factor for survival) to
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         plus FOLFOXIRI or FOLFOX [
         <a href="#rid26">
          26
         </a>
         ]. In a preliminary report presented at the 2019 annual American Society of Clinical Oncology (ASCO) meeting, initial triplet therapy was associated with significantly improved disease-free survival, the primary endpoint (median 12.4 versus 9.3 months); there was a trend toward improved OS that was not statistically significant (22.3 versus 17.6 months). Patients treated with the triplet regimen had significantly higher rates of grade 3 or 4 asthenia, diarrhea, and febrile neutropenia. The use of circulating tumor cells for clinical decision-making is not yet a standard approach, but it is the subject of active ongoing research.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The benefits of initial triplet therapy combined with a biologic agent are further supported by two additional studies:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the phase II randomized VOLFI trial, in which 96 patients with
         <em>
          RAS
         </em>
         wild-type mCRC were randomly assigned to modified FOLFOXIRI with or without
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         [
         <a href="#rid24">
          24
         </a>
         ], the addition of panitumumab to modified FOLFOXIRI significantly improved the objective response rate (87 versus 61 percent) and the rate of secondary resection of metastases (33 versus 12 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An individual patient data meta-analysis of five trials comparing FOLFOXIRI plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         versus a doublet plus bevacizumab (from the CHARTA, OLIVIA, STEAM, TRIBE and TRIBE2 trials) concluded that patients assigned to a triplet regimen plus bevacizumab had significantly better median OS (28.9 versus 24.5 months), median PFS (12.2 versus 9.9 months), objective response rate (65 versus 54 percent), and a modestly but significantly higher R0 resection rate (16 versus 12 percent, p = 0.07) [
         <a href="#rid25">
          25
         </a>
         ]. These benefits were counterbalanced by higher rates of grade 3 or 4 neutropenia (46 versus 22 percent), febrile neutropenia (6.3 versus 3.7 percent), and diarrhea (18 versus 8 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h4">
          Initial doublet combinations versus sequential single agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who are able to tolerate it, we suggest combination chemotherapy with a doublet (FOLFOX, CAPOX [XELOX], or FOLFIRI  (
         <a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">
          table 3
         </a>
         )) rather than sequential single-agent therapy for initial treatment of mCRC, particularly for those who have limited liver metastases that might become potentially resectable. This recommendation is consistent with consensus-based guidelines from the NCCN, ESMO, and ASCO [
         <a href="#rid10">
          10-12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Patients with initially unresectable metastases'
         </a>
         .)
        </p>
        <p>
         The three active conventional chemotherapy agents for mCRC are fluoropyrimidines,
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         , and
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         . The proportion of patients exposed to all three drug classes during the course of therapy for mCRC correlates strongly with median survival in all large published phase III trials over the last decade. (See
         <a class="local">
          'Subsequent treatment and the continuum of care model'
         </a>
         above.)
        </p>
        <p>
         In view of this observation, it has been argued that sequential use of active single agents might be preferable to initial combination chemotherapy. This approach could conceivably reduce the overall toxicity of therapy while at the same time providing comparable OS since patients would eventually be exposed to all active agents.
        </p>
        <p>
         The issue of initial combination versus single-agent therapy was directly addressed in two European trials (FOCUS and CAIRO), neither of which showed that survival was adversely impacted by initial single-agent therapy [
         <a href="#rid29">
          29,30
         </a>
         ] However, the median survival for all groups in both trials was lower than expected for modern chemotherapy.
        </p>
        <p>
         One possible reason is the low number of patients who eventually received all three active drugs in both trials. Furthermore, neither trial used
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         or
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         as either first-line or salvage therapy. These agents improve PFS, and bevacizumab also improves OS when used in the first-line regimen. (See
         <a class="local">
          'Role of biologics'
         </a>
         below.)
        </p>
        <p>
         Some of these issues were addressed in a third trial, the XELAVIRI trial, which randomly assigned 421 patients with untreated mCRC to a fluoropyrimidine plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , followed by the addition of
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         at progression, versus initial combined therapy with all three agents [
         <a href="#rid31">
          31
         </a>
         ]. Only 63 percent of patients treated with initial sequential therapy received irinotecan at some point in the course of their treatment, compared with 100 percent in the combination therapy group. Although sequential therapy was shown not to be noninferior to combination therapy for time to failure of strategy (the primary endpoint), survival was not significantly different (median OS 23.5 versus 21.1 months). An unplanned subgroup analysis suggested that initial combination therapy particularly benefited patients with wild-type
         <em>
          RAS
         </em>
         /
         <em>
          BRAF
         </em>
         tumors.
        </p>
        <p>
         Thus, the available evidence continues to support initial combination chemotherapy for most patients, particularly for those whose metastases might be potentially resectable after an initial chemotherapy response. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Patients with initially unresectable metastases'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H378682433">
         <span class="h4">
          FOLFOX versus FOLFIRI
         </span>
         <span class="headingEndMark">
          —
         </span>
         FOLFOX and FOLFIRI  (
         <a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">
          table 3
         </a>
         ) are both considered acceptable choices for doublet first-line therapy, with similar efficacy and a comparable, albeit different, side effect profile; the now obsolete bolus
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         /FU/LV (IFL) regimen should not be used. This recommendation is consistent with consensus-based guidelines from the NCCN and ESMO [
         <a href="#rid10">
          10,11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/85679.html" rel="external">
          "Treatment protocols for small and large bowel cancer"
         </a>
         .)
        </p>
        <p>
         Multiple trials have demonstrated the benefit of adding
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         to FU/LV [
         <a href="#rid32">
          32-35
         </a>
         ], and the benefit of adding
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         to FU/LV [
         <a href="#rid36">
          36-38
         </a>
         ] for the first-line treatment of mCRC. Furthermore, the available data from head-to-head comparisons suggest that outcomes with first-line oxaliplatin/FU/LV and irinotecan/FU/LV are similar, at least when short-term infusional FU regimens are used:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          INT 9741
         </strong>
         – The benefit of FOLFOX was initially established in the pivotal North Central Cancer Treatment Group (NCCTG)/US Intergroup trial N9741, which compared IFL (weekly bolus FU/LV plus
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         for four of every six weeks) to the FOLFOX4  (
         <a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">
          table 3
         </a>
         ) regimen and to a combination of irinotecan plus
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         without FU (IROX) [
         <a href="#rid39">
          39
         </a>
         ]. All efficacy parameters as well as the toxicity profile favored FOLFOX4 over IFL. Largely based upon these results, FOLFOX, in particular modified FOLFOX6, in which the entire FU dose is given over 46 hours without a day 2 bolus dose of LV  (
         <a class="graphic graphic_table graphicRef50132" href="/z/d/graphic/50132.html" rel="external">
          table 5
         </a>
         ), has become the most commonly used first-line chemotherapy backbone for mCRC in the United States [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          European/Asian trials
         </strong>
         – In contrast to bolus IFL, regimens that incorporate
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         plus short-term infusional rather than bolus FU/LV (ie, the FOLFIRI regimen)  (
         <a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">
          table 3
         </a>
         ) appear to be at least as effective as the FOLFOX regimen:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A French phase III trial of 220 patients compared FOLFOX6 versus FOLFIRI; both groups were allowed crossover at progression [
         <a href="#rid41">
          41
         </a>
         ]. There were no differences in pertinent efficacy parameters (response rate, PFS, and OS, approximately 21 months in both groups).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An Italian phase III study of 336 patients randomized to FOLFOX4 versus FOLFIRI confirmed these findings [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Noninferiority of FOLFIRI plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         as compared with FOLFOX plus bevacizumab for first-line therapy of mCRC was also noted in the West Japan Oncology Group study 4407G and in the United States MAVERICC trials [
         <a href="#rid43">
          43,44
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1707131799">
         <span class="h5">
          Treatment-related toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         In practice, the choice between first-line FOLFIRI or FOLFOX is often based upon expected treatment-related toxicity. The rates of grade 3 or higher adverse effects are very similar between these two regimens, although the types of toxicity differ. FOLFIRI might be preferred over FOLFOX in a patient who received adjuvant therapy with an oxaliplatin-based regimen within the preceding 12 months.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Irinotecan
         </strong>
         – The main adverse events reported with FOLFIRI-type regimens are diarrhea (which is much less of an issue with short-term infusional rather than bolus FU regimens), fatigue, alopecia, and neutropenia. In general, toxicity is not cumulative and
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         can usually be continued until disease progression. (See
         <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">
          "Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hepatic metabolism, hyperbilirubinemia, and UGT1A1 polymorphisms
         </strong>
         – One major issue with
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         is the interpatient variability in pharmacokinetics that correlates poorly with body surface area-based dosing [
         <a href="#rid45">
          45-48
         </a>
         ]. Pharmacokinetic variability has been related to individual differences related to polymorphisms in the enzyme UGT that inactivates the active metabolite of irinotecan (SN-38) and in circumstances that interfere with the biliary excretion of the metabolite [
         <a href="#rid49">
          49-51
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Even modest elevations in serum bilirubin increase the risk for severe neutropenia and diarrhea [
         <a href="#rid49">
          49
         </a>
         ], and some clinicians advise preemptive dose reduction in this setting. (See
         <a class="medical medical_review" href="/z/d/html/2837.html" rel="external">
          "Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents", section on 'Irinotecan and liposomal irinotecan'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) is a polymorphic enzyme that is involved in
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         metabolism; some common variants, especially homozygosity for the *28/*28 variant results in reduced enzymatic activity, and therefore slower inactivation of SN-38, the active metabolite. This leads to excess toxicity, mainly neutropenia, but also diarrhea. Approximately 50 percent of the North American population carries one or two copies of UGT1A1 *28 and therefore experience slower inactivation of SN-38 than those who do not harbor one of these alleles. Individuals who are homozygous for
         <em>
          UGT1A1
         </em>
         *28 have Gilbert's syndrome (unconjugated hyperbilirubinemia). (See
         <a class="medical medical_review" href="/z/d/html/3578.html" rel="external">
          "Gilbert syndrome", section on 'Genetics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         The initial
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         dose may be reduced for patients known to be homozygous for the
         <em>
          UGT1A1
         </em>
         *28 or *6 (alleles (*28/*28, *6/*6) or a compound heterozygote for the
         <em>
          UGT1A1
         </em>
         *6/*28 alleles (*6/*28) to limit the likelihood of dose-limiting neutropenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         There is insufficient evidence to recommend preemptive testing for
         <em>
          UGT1A1
         </em>
         genotypes associated with a poor metabolizer phenotype in all patients beginning
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         . For individuals with a known
         <em>
          UGT1A1
         </em>
         allele that is associated with reduced enzyme activity (eg, those known to have Gilbert's syndrome), lower doses of irinotecan are indicated, although there is no consensus on how low the initial dose should be. Many clinicians would pursue an initial 50 percent dose reduction in such cases with further adjustments based on tolerance of that dose. Patients who experience severe irinotecan toxicity require a dose reduction regardless of t
         <em>
          he UGT1A1
         </em>
         genotype.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         This subject is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/83810.html" rel="external">
          "Dosing of anticancer agents in adults", section on 'UGT1A1 polymorphisms and irinotecan'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">
          "Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'UGT1A1 polymorphisms'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Steatosis and steatohepatitis
         </strong>
         –
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          Irinotecan
         </a>
         has also been associated with steatosis, steatohepatitis, and hepatic vascular damage. Steatosis and steatohepatitis are observed more frequently in patients with a higher body mass index (BMI), which may explain why this complication is reported more frequently in United States studies (in which median BMIs are higher than in European populations), while vascular lesions are seen more commonly in Europeans. The potential for altered liver function related to irinotecan-associated steatohepatitis is an important consideration for patients who are candidates for resection of liver metastases. More severe liver dysfunction associated with prolonged irinotecan treatment may affect function of the liver remnant after resection. This subject is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Post-treatment assessment and duration of neoadjuvant therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oxaliplatin
         </strong>
         –
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          Oxaliplatin
         </a>
         is less likely to cause diarrhea and alopecia than is
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         . Severe myelosuppression can be largely avoided if a non-bolus FU-containing regimen is used (eg, modified FOLFOX7,  (
         <a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">
          table 3
         </a>
         )) [
         <a href="#rid52">
          52,53
         </a>
         ] or CAPOX. Oxaliplatin is safe in patients with hepatic or renal dysfunction [
         <a href="#rid54">
          54,55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2834.html" rel="external">
          "Nephrotoxicity of chemotherapy and other cytotoxic agents", section on 'Oxaliplatin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Neuropathy
         </strong>
         – The dose-limiting side effect of
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         is a cumulative, late-onset predominantly sensory neuropathy, which may require drug discontinuation despite ongoing tumor response. It occurs with increasing frequency above cumulative doses of 680 mg/m
         <sup>
          2
         </sup>
         [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Given the expectation that over the continuum of care, patients will likely be exposed to both FOLFOX and FOLFIRI, patients with preexisting neuropathy and those for whom the development of a severe sensory neuropathy might jeopardize their livelihood (eg, a professional musician), or others who place a high value on delaying potentially debilitating and long-lasting neuropathy for as long as possible might be better served with initial irinotecan-based rather than oxaliplatin-based therapy. (See
         <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">
          "Overview of neurologic complications of platinum-based chemotherapy", section on 'Oxaliplatin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         However, long-term neurotoxicity can be mitigated by intermittent oxaliplatin-free intervals, as has been addressed in multiple randomized trials. When FOLFOX with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         is used for first-line therapy, the available data suggest that it is reasonable to discontinue
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         temporarily prior to the development of clinically significant neuropathy, while maintaining a fluoropyrimidine with or without bevacizumab. Options for prevention of oxaliplatin-induced peripheral neuropathy and the design and results of trials of intermittent oxaliplatin-free therapy are discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/94976.html" rel="external">
          "Prevention and treatment of chemotherapy-induced peripheral neuropathy", section on 'Oxaliplatin'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'Continuous versus intermittent therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hepatic sinusoidal injury
         </strong>
         –
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          Oxaliplatin
         </a>
         is associated with dose-dependent hepatic sinusoidal injury, which can be identified radiographically by the development of splenomegaly resulting from an increase in portal venous pressure [
         <a href="#rid57">
          57-61
         </a>
         ]. The potential clinical impact of hepatic sinusoidal injury is best described in patients undergoing hepatic metastasectomy for colorectal cancer liver metastases; patients who receive preoperative oxaliplatin have increased bleeding risk and postoperative morbidity. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Post-treatment assessment and duration of neoadjuvant therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Concomitant administration of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         may protect against the development of oxaliplatin-induced hepatic sinusoidal injury [
         <a href="#rid62">
          62,63
         </a>
         ]. As an example, in an analysis of 200 randomly selected patients with unresectable mCRC who were randomly assigned to a first-line fluoropyrimidine- and oxaliplatin-containing regimen with or without bevacizumab in the NO16966 trial, the six-month cumulative incidence rate of a 50 percent or greater increase in spleen size was 21 versus 48 percent, and the cumulative rate of thrombocytopenia (&lt;100,000/mm
         <sup>
          3
         </sup>
         ) was 19 versus 51 percent for bevacizumab versus no bevacizumab [
         <a href="#rid63">
          63
         </a>
         ]. Patients with a large spleen prior to chemotherapy appeared to be at highest risk for this toxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In contrast to patients with potentially resectable CRC liver metastases, the clinical impact of a reduction in thrombocytopenia on efficacy outcomes in the setting of unresectable mCRC is uncertain. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Issues related to bevacizumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Partial splenic embolization may overcome prolonged hypersplenism-related thrombocytopenia, permitting safe continuation of oxaliplatin-containing regimens [
         <a href="#rid64">
          64-67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Infusion reactions
         </strong>
         – Acute infusion reactions, characterized by rash, fever, and ocular and respiratory symptoms of varying severity, have been reported in up to 25 percent of patients treated with
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         . Patients with mild reactions can continue to be treated with oxaliplatin by premedication with
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         and steroids, and by lengthening the infusion duration and/or decreasing the dose. (See
         <a class="medical medical_review" href="/z/d/html/2835.html" rel="external">
          "Infusion reactions to systemic chemotherapy", section on 'Oxaliplatin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h4">
          Oral fluoropyrimidines
         </span>
        </p>
        <p class="headingAnchor" id="H44522116">
         <span class="h5">
          Capecitabine doublets
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          Capecitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         (CAPOX, XELOX) is a reasonable substitute for FOLFOX in the palliative therapy of mCRC. However, combinations of capecitabine with
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         (XELIRI, CAPIRI) cannot be routinely recommended as a valid substitute for FOLFIRI, at least for American patients, because of toxicity concerns. For most patients, our preference remains delivering irinotecan with infusional
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         (FU). This recommendation is consistent with consensus-based guidelines from the NCCN and ESMO [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Capecitabine
         </strong>
         <strong>
          plus
         </strong>
         <strong>
          oxaliplatin
         </strong>
         – CAPOX (XELOX) is a reasonable alternative for first-line therapy of mCRC in patients for whom ambulatory infusional FU therapy using a pump is not feasible or desired. The available data suggest that CAPOX has approximately similar antitumor efficacy, but there is a possibility of more toxicity (especially thrombocytopenia and hand-foot syndrome, possibly diarrhea) as compared with infusional FU/
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         combinations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For American patients, we consider the standard regimen to be
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         850 mg/m
         <sup>
          2
         </sup>
         twice daily for 14 of every 21 days (as was used in the TREE-2 trial) plus
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         130 mg/m
         <sup>
          2
         </sup>
         on day 1 over two hours  (
         <a class="graphic graphic_table graphicRef61781" href="/z/d/graphic/61781.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid68">
          68,69
         </a>
         ]. Oncologists in Europe and Asia more commonly start with capecitabine 1000 mg/m
         <sup>
          2
         </sup>
         twice daily, as was used in TREE-1 [
         <a href="#rid68">
          68
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/85679.html" rel="external">
          "Treatment protocols for small and large bowel cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A lower
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         dose (eg, 85 mg/m
         <sup>
          2
         </sup>
         over two hours on day 1) with
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         (850 or 1000 mg/m
         <sup>
          2
         </sup>
         twice daily on days 2 to 15) could be considered for older adult patients [
         <a href="#rid70">
          70
         </a>
         ]. More intensive regimens (eg, week on, week off therapy with both capecitabine and oxaliplatin [
         <a href="#rid71">
          71
         </a>
         ]) may be more active, but direct comparisons with standard doses are not yet available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Multiple randomized trials and a systematic review comparing CAPOX versus other fluoropyrimidine/
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         combinations, such as FOLFOX, have concluded comparable efficacy, but a different toxicity profile [
         <a href="#rid68">
          68,69,72-75
         </a>
         ]. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The phase II TREE-1 trial randomly assigned 150 patients to modified FOLFOX6  (
         <a class="graphic graphic_table graphicRef50132" href="/z/d/graphic/50132.html" rel="external">
          table 5
         </a>
         ), CAPOX (
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         1000 mg twice daily for 14 of every 21 days plus
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         130 mg/m
         <sup>
          2
         </sup>
         on day one), or bFOL (bolus FU 500 mg/m
         <sup>
          2
         </sup>
         , and LV 20 mg/m
         <sup>
          2
         </sup>
         weekly for three of every four weeks plus oxaliplatin 85 mg/m
         <sup>
          2
         </sup>
         on days 1 and 15) [
         <a href="#rid68">
          68
         </a>
         ]. The differences between FOLFOX and CAPOX in response rates, time to progression and median survival were not significant  (
         <a class="graphic graphic_table graphicRef66587" href="/z/d/graphic/66587.html" rel="external">
          table 7
         </a>
         ). Patients in the CAPOX group had the highest rates of hand-foot syndrome, grade 3 or 4 nausea/vomiting and neuropathy (38 and 21 percent), and more often discontinued therapy because of toxicity. The FOLFOX6 group had the highest rate of grade 3 or 4 neutropenia (53 versus 15 percent with CAPOX). Rates of grade 3 or 4 diarrhea were the same (31 percent) in both groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The single most influential trial addressing the relative benefit of
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         as a substitute for short-term infusional FU/LV is the Roche-sponsored NO16966 trial in which 634 patients were randomly assigned to CAPOX versus FOLFOX4  (
         <a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">
          table 3
         </a>
         ) for first-line therapy [
         <a href="#rid72">
          72
         </a>
         ]. An additional 1400 patients were accrued after a protocol amendment added a second randomization to
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         versus placebo. In the latest report, for the direct comparison of CAPOX versus FOLFOX4, there was no relevant difference in OS (19.8 versus 19.5 months) [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Practicing oncologists should, however, consider the following issues before routinely adopting CAPOX as a preferred alternative to FOLFOX:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The appropriate dose of
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         is not well defined, at least for American patients. There appear to be large regional differences in the tolerance to capecitabine and other fluoropyrimidines [
         <a href="#rid77">
          77
         </a>
         ], which might in part be based on population-specific pharmacogenomic variability (eg, Asian patients seem to tolerate fluoropyrimidines better than non-Asian patients [
         <a href="#rid77">
          77
         </a>
         ]). However, lifestyle or dietary differences (eg, folate intake) could also contribute.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The commonly applied dosing schedule of
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         in European trials (1000 mg/m
         <sup>
          2
         </sup>
         twice daily, for 14 of every 21 days) when added to
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         (130 mg/m
         <sup>
          2
         </sup>
         on day 1 of a three-week cycle) was unacceptably toxic in the United States TREE-1 trial  (
         <a class="graphic graphic_table graphicRef66587" href="/z/d/graphic/66587.html" rel="external">
          table 7
         </a>
         ) [
         <a href="#rid68">
          68
         </a>
         ]. Reduction of the capecitabine dose in the TREE-2 trial to 850 mg/m
         <sup>
          2
         </sup>
         twice daily was associated with a markedly improved safety profile. We consider capecitabine 850 mg/m
         <sup>
          2
         </sup>
         twice daily plus oxaliplatin 130 mg/m
         <sup>
          2
         </sup>
         on day 1 of each cycle to represent a standard regimen for American patients  (
         <a class="graphic graphic_table graphicRef61781" href="/z/d/graphic/61781.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A central venous access line is often needed for reasons other than infusional FU in patients with mCRC. Because a significant number of patients report local pain when
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         is infused via peripheral vein, many centers routinely infuse the drug centrally. Furthermore, recognizing that mCRC is a chronic disease with the need for multiple sequential chemotherapy regimens, many patients will undergo placement of a central venous line at some point in the course of treatment simply because of inadequate peripheral venous access.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Capecitabine
         </strong>
         <strong>
          plus
         </strong>
         <strong>
          irinotecan
         </strong>
         – While CAPOX is a valid substitute for FOLFOX (with the above caveats), the situation is different for combinations of
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         with
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         (XELIRI, CAPIRI) as an alternative to FOLFIRI. Capecitabine and irinotecan have partially overlapping toxicity profiles, particularly with regard to diarrhea. The potential for greater toxicity reduces the therapeutic advantage of an irinotecan/capecitabine combination and makes the selection of appropriate doses and schedules for this combination more crucial than for CAPOX. (See
         <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">
          "Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Six early trials (most conducted outside of North America) compared the safety and efficacy of the XELIRI and FOLFIRI regimens with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         [
         <a href="#rid78">
          78-83
         </a>
         ]; the
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         doses in the XELIRI arms ranged from 200 to 250 mg/m
         <sup>
          2
         </sup>
         on day 1 of each 21-day cycle, and all trials used
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         1000 mg/m
         <sup>
          2
         </sup>
         twice daily on days 1 to 14; the authors have generally concluded that both regimens had similar efficacy and similar adverse event profiles [
         <a href="#rid84">
          84
         </a>
         ]. However, higher rates of grade 3 or 4 diarrhea have been reported with XELIRI as compared with FOLFIRI in several of the trials [
         <a href="#rid78">
          78,79,83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Regional differences in
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         tolerability [
         <a href="#rid77">
          77
         </a>
         ] make it difficult to translate toxicity and efficacy findings generated in trials conducted outside of the United States [
         <a href="#rid30">
          30
         </a>
         ] into American patients. This problem was particularly apparent in the phase III BICC-C trial, which compared three different approaches to combining
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         with infusional FU (FOLFIRI), bolus FU (modified IFL), or capecitabine (XELIRI) using the standard European doses of irinotecan (250 mg/m
         <sup>
          2
         </sup>
         day 1) and capecitabine (1000 mg/m
         <sup>
          2
         </sup>
         twice daily, on days 1 to 14 of every three-week cycle) [
         <a href="#rid78">
          78
         </a>
         ]. No prespecified dose reduction for irinotecan and capecitabine for older adult patients (as suggested by other authors [
         <a href="#rid85">
          85
         </a>
         ]) was implemented. FOLFIRI emerged as the undisputed winner of the head-to-head comparison of all three regimens in terms of efficacy and tolerability. XELIRI was associated with a higher rate of grade 3/4 adverse events, in particular, diarrhea (48 versus 14 percent), nausea (18 versus 9 percent), vomiting (16 versus 9 percent), and dehydration (19 versus 6 percent). Higher rates of grade 3 and 4 diarrhea with XELIRI as compared with FOLFIRI have been seen in other trials as well [
         <a href="#rid79">
          79,83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A modified dose XELIRI regimen may be more tolerable, at least in Asian patients [
         <a href="#rid86">
          86
         </a>
         ]. Despite this trial and the conclusions of the meta-analysis [
         <a href="#rid84">
          84
         </a>
         ], our preference remains delivering
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         with infusional FU, particularly for older patients, because of potential toxicity concerns.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H44522371">
         <span class="h5">
          Oxaliplatin plus S-1
         </span>
         <span class="headingEndMark">
          —
         </span>
         Where available, S-1 plus
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         (SOX) represents an acceptable first-line oxaliplatin-containing chemotherapy regimen, at least for Asian patients.
        </p>
        <p>
         S-1 is an oral fluoropyrimidine that includes three different agents: ftorafur (tegafur), gimeracil (5-chloro-2,4 dihydropyridine, a potent inhibitor of dihydropyrimidine dehydrogenase [DPD]), and oteracil (potassium oxonate, which inhibits phosphorylation of intestinal FU, thought responsible for treatment-related diarrhea). It is available in most countries outside of the United States. At least two randomized trials, both conducted in Asian populations, have demonstrated the noninferiority of SOX compared with
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         plus
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         , or FOLFOX/
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         :
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SOX was directly compared with CAPOX in a multicenter randomized Korean phase III trial of 340 patients with previously untreated mCRC [
         <a href="#rid87">
          87
         </a>
         ]. The design was characterized as a noninferiority trial with an upper boundary of the PFS HR of 1.43 (meaning that a 43 percent detriment in PFS would have been considered acceptable to define noninferiority). SOX was statistically noninferior to standard CAPOX in terms of PFS (HR 0.79, 95% CI 0.6-1.04) and demonstrated a significantly higher response rate (48 versus 36 percent), but more grade 3 or 4 neutropenia, thrombocytopenia, and diarrhea.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SOX in combination with
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         was compared with modified FOLFOX6 plus bevacizumab in the randomized SOFT study of 512 Japanese patients with previously untreated mCRC. SOX plus bevacizumab was noninferior to FOLFOX/bevacizumab (median PFS 11.5 versus 11.7 months), and objective response rates were similar (61 versus 62 percent) [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2755622220">
         <span class="h5">
          UFT-containing doublets
         </span>
         <span class="headingEndMark">
          —
         </span>
         Where available, combinations of tegafur plus uracil (UFT) with
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         (TEGAFOX, UFOX) or
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         (TEGAFIRI) are acceptable first-line options for fluoropyrimidine plus oxaliplatin-containing and irinotecan-containing chemotherapy, respectively.
        </p>
        <p>
         UFT is a 1:4 molar combination of ftorafur (tegafur) with uracil, which competitively inhibits the degradation of FU, resulting in sustained plasma and intratumoral concentrations [
         <a href="#rid89">
          89
         </a>
         ]. Combinations of UFT with
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         (TEGAFIRI) and
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         (TEGAFOX, UFOX) appear to be effective and well tolerated, with similar efficacy and tolerability to the corresponding FU- and capecitabine-based regimens [
         <a href="#rid90">
          90-94
         </a>
         ]. UFT is not available in the United States.
        </p>
        <p class="headingAnchor" id="H2752145753">
         <span class="h4">
          IROX
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary use of the
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         plus
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         (IROX) regimen is in patients who are unable to tolerate FU, typically because of deficiency in the fluoropyrimidine-metabolizing enzyme DPD. (See
         <a class="medical medical_review" href="/z/d/html/2824.html" rel="external">
          "Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Management of DPD-deficient patients'
         </a>
         .)
        </p>
        <p>
         The available data on IROX as a first-line regimen are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IROX regimen was inferior to first-line
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         plus infusional FU and LV (FOLFOX) in United States Intergroup trial 9741, and it was more toxic in older adult individuals [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similarly, a report of the FIRE trial (IROX versus
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         plus infusional FU and LV [FOLFIRI] as first-line treatment of colorectal cancer) suggested that the regimens had similar efficacy (objective response rate 41 percent with both regimens; median survival 22 and 19 months for FOLFIRI and IROX, respectively) [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H43745663">
         <span class="h3">
          Role of biologics
         </span>
         <span class="headingEndMark">
          —
         </span>
         The addition of a biologic agent to the chemotherapy backbone may achieve additional efficacy in some patients; however, potential benefits need to be weighed against potential adverse effects. There are two "biologics" options,
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         and biosimilars (antiangiogenic monoclonal antibodies) and
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         /
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         , which are both anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, and only effective in
         <em>
          RAS/BRAF
         </em>
         wild-type tumors. If this approach is chosen, selection of the biologic agent is based on several factors, including
         <em>
          RAS
         </em>
         /
         <em>
          BRAF
         </em>
         mutation status, primary tumor site, patient preference, and eligibility for bevacizumab. This approach is discussed in further detail below. (See
         <a class="local">
          'EGFR inhibitors versus bevacizumab and the influence of tumor sidedness'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h4">
          Efficacy and toxicity of bevacizumab and biosimilars
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          Bevacizumab
         </a>
         is a humanized monoclonal antibody that targets vascular endothelial growth factor-A (VEGF-A), a member of a family of VEGF receptor-activating ligands. Biosimilars for bevacizumab have also been approved by the US Food and Drug Administration (FDA) [
         <a href="#rid97">
          97,98
         </a>
         ].
        </p>
        <p>
         CRC was the first malignancy for which clear evidence for efficacy of an anti-VEGF strategy was demonstrated in randomized trials. In a pivotal early trial, the addition of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         to the bolus IFL regimen significantly improved response rates (45 versus 35 percent), time to tumor progression (11 versus 6 months), and OS (20 versus 16 months) [
         <a href="#rid99">
          99
         </a>
         ]. Since then, benefit for adding bevacizumab to a variety of fluoropyrimidine,
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         , and oxaliplatin-containing regimens used for first-line therapy has been confirmed, although the magnitude of both the OS and PFS benefits are relatively modest, especially for relatively more effective chemotherapy backbones such as FOLFOX and FOLFIRI. Nevertheless, the available data support a benefit for adding bevacizumab to cytotoxic backbone regimens that contain either
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         or irinotecan, both, or a fluoropyrimidine alone.
        </p>
        <p>
         As an example, in a pooled analysis of trials comparing chemotherapy with and without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         in the first-line setting, the addition of bevacizumab was associated with a significant 19 percent reduction in the risk of death (HR for death 0.81, 95% CI 0.70-0.93), but this translated into a median OS advantage of only two months (19.8 versus 17.6 months) [
         <a href="#rid100">
          100
         </a>
         ]. PFS was also significantly improved (HR 0.58, 95% CI 0.46-0.73) but the advantage was also limited to approximately two months (median PFS 9.1 versus 6.9 months). These modest advances come at a cost of treatment-related side effects, including bleeding, hypertension, bowel perforation, and thromboembolic events. However, although there are these potentially serious outcomes, they are not common. (See
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         .)
        </p>
        <p>
         These issues have prompted debate as to whether there is enough evidence to justify the routine use of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         as a component of first-line chemotherapy in patients with inoperable mCRC, whether there are subgroups of patients for whom the benefit of bevacizumab does not outweigh its risks, and whether there are patients who should not receive bevacizumab at all. This remains a controversial area.
        </p>
        <p class="headingAnchor" id="H1922362062">
         <span class="h5">
          With oxaliplatin regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immediately following the approval of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         in the United States in 2004, the significant difference in outcome favoring FOLFOX over bolus IFL reported shortly thereafter in the US Intergroup N9741 trial [
         <a href="#rid39">
          39
         </a>
         ] led many oncologists to choose FOLFOX as the chemotherapy backbone for the addition of bevacizumab, despite the lack of clinical trial results demonstrating that this regimen was better than any other. (See
         <a class="local">
          'FOLFOX versus FOLFIRI'
         </a>
         above.)
        </p>
        <p>
         At least four trials support a modest benefit for adding
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         to FOLFOX [
         <a href="#rid68">
          68,101-103
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the phase II randomized TREE-2 trial, 223 previously untreated patients were randomly assigned to
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         (5 mg/kg every two weeks) and one of the three different oxaliplatin- and FU-containing regimens used in the TREE-1 trial [
         <a href="#rid68">
          68
         </a>
         ]. Bevacizumab substantially improved the response rates of all of the regimens  (
         <a class="graphic graphic_table graphicRef66587" href="/z/d/graphic/66587.html" rel="external">
          table 7
         </a>
         ). Median OS was 23.7 months for the combined groups receiving bevacizumab (versus 18.2 months for the combined non-bevacizumab-treated groups). However, bevacizumab also increased rates of grade 3 or 4 hypertension  (
         <a class="graphic graphic_table graphicRef66587" href="/z/d/graphic/66587.html" rel="external">
          table 7
         </a>
         ), bowel perforation (2 percent overall), impaired wound healing (n = 3) and bleeding events (45 versus 22 percent in the groups treated with FOLFOX with and without bevacizumab).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Modest benefit for the addition of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         was also suggested in the NO 16966 trial of FOLFOX or CAPOX with and without bevacizumab [
         <a href="#rid102">
          102
         </a>
         ]. There was a significant PFS for the addition of bevacizumab; however, the magnitude of benefit was smaller than expected, and neither median OS nor response rates were significantly higher in patients who received bevacizumab  (
         <a class="graphic graphic_table graphicRef72526" href="/z/d/graphic/72526.html" rel="external">
          table 8
         </a>
         ). Bevacizumab-treated patients discontinued treatment more often because of toxicity than disease progression; the authors postulated that failure to continue therapy until disease progression offset the benefit of adding bevacizumab.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2275741592">
         <span class="h5">
          Irinotecan regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         In an early trial of 813 patients who were randomly assigned to
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         /FU/LV (IFL) with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , bevacizumab improved the objective response rate (45 versus 35 percent), and significantly improved time to tumor progression (11 versus 6 months) and median survival (20 versus 16 months) [
         <a href="#rid99">
          99
         </a>
         ]. As a result of these data, bevacizumab received broad approval in the United States in combination with FU for first-line treatment of mCRC.
        </p>
        <p>
         The bolus IFL regimen has fallen out of favor due to the more favorable gastrointestinal toxicity profile of regimens that contain short-term infusional FU/LV (eg, FOLFIRI)  (
         <a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">
          table 3
         </a>
         ). The available data on
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         plus FOLFIRI are limited and conflicting:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the complex BICC-C trial, patients with previously untreated mCRC were assigned to FOLFIRI, modified IFL, or
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         /
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         , all arms with or without
         <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">
          celecoxib
         </a>
         ; a later amendment added
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         to patients on the FOLFIRI and IFL arms [
         <a href="#rid78">
          78
         </a>
         ]. The median PFS was 11.2 months in the small group of 61 patients receiving bevacizumab/FOLFIRI (8.3 months for bevacizumab/IFL), and the objective response rate was 58 percent (53 percent with bevacizumab/IFL). In a later report, at a median follow-up of 34 months, median survival in the group receiving FOLFIRI/bevacizumab was 28 months while it was 19.2 months with bevacizumab/IFL [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         On the other hand, a lack of survival benefit for the addition of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         to first-line FOLFIRI was shown in two European trials [
         <a href="#rid105">
          105,106
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H769588270">
         <span class="h5">
          FOLFOXIRI
         </span>
         <span class="headingEndMark">
          —
         </span>
         The available data using regimens that combine the triplet chemotherapy backbone FOLFOXIRI plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         are discussed above. There are no trials of FOLFOXIRI with or without bevacizumab. (See
         <a class="local">
          'Three- versus two-drug combinations'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1125118686">
         <span class="h5">
          Is first-line bevacizumab justified in all patients?
         </span>
         <span class="headingEndMark">
          —
         </span>
         In some trials,
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         appears to provide greater incremental gain in PFS when it is added to "weaker" chemotherapy regimens such as FU/LV or bolus IFL [
         <a href="#rid99">
          99,107
         </a>
         ] than to more active regimens such as FOLFOX or FOLFIRI. As a result, the effectiveness of adding bevacizumab to standard first-line treatment with either FOLFOX or FOLFIRI has been challenged [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          Bevacizumab
         </a>
         is expensive (although less expensive biosimilars for bevacizumab are available and approved [
         <a href="#rid97">
          97,98
         </a>
         ]), its benefits are modest at best [
         <a href="#rid101">
          101
         </a>
         ], and use of the drug is associated with a number of potentially serious side effects, including proteinuria, hypertension, bleeding, bowel perforation, impaired wound healing, arterial thromboembolic events and reversible posterior multifocal leukoencephalopathy. (See
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4835.html" rel="external">
          "Reversible posterior leukoencephalopathy syndrome"
         </a>
         .)
        </p>
        <p>
         The benefit of a bevacizumab-containing regimen is especially debated for patients undergoing initial (neoadjuvant) chemotherapy for potentially resectable liver metastases. Many clinicians do not use
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         in conjunction with a cytotoxic chemotherapy backbone in this setting, citing the marginal benefits and risk for major complications. Others restrict the use of bevacizumab to those patients with
         <em>
          RAS
         </em>
         /
         <em>
          BRAF
         </em>
         -mutated tumors (ie, those for which use of an EGFR inhibitor is contraindicated) who are undergoing conversion therapy for initially unresectable disease [
         <a href="#rid103">
          103
         </a>
         ]. This subject is discussed in detail elsewhere.
        </p>
        <p>
         For patients with
         <em>
          RAS
         </em>
         and
         <em>
          BRAF
         </em>
         <strong>
          wild-type
         </strong>
         tumors, an important question is whether a bevacizumab-containing regimen provides superior outcomes as compared with an initial regimen that contains an EGFR inhibitor. Data suggest that first-line
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         containing regimens may provide superior outcomes for patients with
         <em>
          RAS
         </em>
         /
         <em>
          BRAF
         </em>
         wild-type mCRC with a primary tumor site in the right colon. (See
         <a class="local">
          'EGFR inhibitors versus bevacizumab and the influence of tumor sidedness'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3952404143">
         <span class="h5">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The benefits of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         are counterbalanced by its side effect profile, which includes proteinuria and potentially serious nephrotic syndrome and hypertension, and potentially fatal bleeding, gastrointestinal tract perforation, and arterial and possibly venous thromboembolic events [
         <a href="#rid108">
          108
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h5">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         A minority of patients have upfront contraindications to
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         , although these are not well defined. According to the product labeling, bevacizumab is contraindicated in the setting of recent hemoptysis of &gt;2.5 mL (although this applies mainly to patients with non-small cell lung cancer) and major surgery within 28 days of treatment (and only following complete healing of the incision) [
         <a href="#rid109">
          109
         </a>
         ]. The use of bevacizumab in patients with brain metastases is controversial:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arterial thromboembolic disease
         </strong>
         –
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          Bevacizumab
         </a>
         increases the risk of an ATE. In one meta-analysis, the risk appeared to be higher in those over the age of 65 and in those with a prior history of an ATE [
         <a href="#rid110">
          110
         </a>
         ]. As a result, most clinicians consider that prior ATE within the last 6 to 12 months represents a relative contraindication to bevacizumab, particularly in older adult patients. (See
         <a class="medical medical_review" href="/z/d/html/2512.html" rel="external">
          "Therapy for metastatic colorectal cancer in older adult patients and those with a poor performance status", section on 'Bevacizumab and biosimilars'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Whether
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or other antiplatelet therapy can reduce the risk of ATEs in patients receiving
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         is unclear; at least some data suggest that the use of aspirin does not increase the risk of bleeding during bevacizumab therapy. We tend to avoid bevacizumab in older adult patients with a history of an ATE within six months and consider the use of aspirin in other high-risk patients. This subject is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Arterial thromboembolic events'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Active wound
         </strong>
         –
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          Bevacizumab
         </a>
         impairs wound healing. This fact, plus the relatively long half-life of bevacizumab (20 days), has prompted the general recommendation that elective surgical intervention (eg, liver resection) be deferred for at least 28 days (and preferably for six to eight weeks) after the last dose of the drug. Minor surgery (ie, the need for a central venous access catheter) can safely be performed in patients receiving bevacizumab, but at least two weeks should elapse before additional doses of the drug are administered. In the case of surgical emergencies (eg, bowel perforations), bevacizumab treatment should
         <strong>
          not
         </strong>
         be considered an absolute contraindication to surgery. This subject is addressed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Bevacizumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemorrhage
         </strong>
         –
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          Bevacizumab
         </a>
         is contraindicated if there is a recent history of significant hemoptysis; however, an increased risk of pulmonary hemorrhage has not been described in patients with pulmonary metastases from non-lung primaries. (See
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Special categories of bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Concerns have been raised about a potential increase in the risk of intracerebral hemorrhage in patients treated with
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         who have brain metastases. However, the available data suggest that patients with a history of treated nonhemorrhagic brain metastases probably should not be excluded from systemic therapy with bevacizumab as long as they are not on concurrent anticoagulation. (See
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Intracranial bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          Bevacizumab
         </a>
         should be discontinued permanently in patients who develop severe adverse events during treatment, including gastrointestinal perforation (fistula formation, intra-abdominal abscess), an ATE, wound dehiscence requiring medical intervention, nephrotic syndrome, hypertensive crisis or encephalopathy, or a posterior leukoencephalopathy syndrome. The subject of bevacizumab side effects is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">
          "Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">
          "Cardiovascular toxicities of molecularly targeted antiangiogenic agents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2656939188">
         <span class="h4">
          RAS/BRAF wild-type tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapy with an EGFR inhibitor, either alone or in conjunction with cytotoxic chemotherapy, is an appropriate option for individuals with
         <em>
          RAS/BRAF
         </em>
         wild-type tumors with a left-sided primary. If an EGFR inhibitor is chosen, the choice between
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         and
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         is empiric. The available evidence suggests that antitumor efficacy of single-agent panitumumab is similar to that of cetuximab, and that the two drugs might be interchangeable. (See
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Are cetuximab and panitumumab interchangeable?'
         </a>
         .)
        </p>
        <p>
         However, the incidence of infusion reactions is lower with
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         , which may be relatively more important in geographic areas that have a high incidence of
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         infusion reactions (ie, the middle southeastern region of the United States (North Carolina, Arkansas, Missouri, Virginia, Florida, and Tennessee). (See
         <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">
          "Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Cetuximab'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">
          "Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Panitumumab'
         </a>
         .)
        </p>
        <p>
         If
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         or
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         are chosen for first-line therapy, the chemotherapy backbone should contain infusional FU (ie, FOLFIRI, FOLFOX). Triplet combinations of an EGFR inhibitor plus FOLFOXIRI may also be appropriate in patients who can tolerate more intensive therapy.
        </p>
        <p>
         However:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The benefit of an oxaliplatin-containing regimen plus an EGFR inhibitor prior to resection in patients with potentially resectable colorectal liver metastases is still debated, and many clinicians avoid this combination in such patients. Furthermore, the addition of EGFR antibodies to oxaliplatin-based regimens in which noninfusional fluoropyrimidines are used (eg, XELOX) has not resulted in any benefit, and we recommend against the use of this combination. (See
         <a class="local">
          'Benefit of cetuximab and panitumumab'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Choice of regimen'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We also avoid combining either
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         or
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         with a bevacizumab-containing regimen, a policy that is also supported by the FDA labeling and consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) [
         <a href="#rid10">
          10,11
         </a>
         ]. (See
         <a class="local">
          'Dual antibody therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h5">
          Benefit of cetuximab and panitumumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          Cetuximab
         </a>
         , a mouse/human chimeric monoclonal antibody (MoAb), binds to the EGFR of both tumor and normal cells, competitively inhibiting ligand binding, and inducing receptor dimerization and internalization. It is unclear whether these actions represent the mechanism of antitumor action.
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          Panitumumab
         </a>
         is a fully human MoAb specific for the extracellular domain of EGFR. Because it is fully human, the incidence of infusion reactions is lower as compared with cetuximab.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Plus
         </strong>
         <strong>
          irinotecan
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         First-line
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         was explored in the CRYSTAL trial, in which 1198 patients with previously untreated mCRC were randomly assigned to FOLFIRI with or without cetuximab [
         <a href="#rid111">
          111
         </a>
         ]. Median PFS was modestly but significantly better with cetuximab (8.9 versus 8 months), as was the overall response rate (47 versus 39 percent), but this did not translate into a significant OS benefit. However, in a later report, among patients with wild-type
         <em>
          KRAS
         </em>
         , response rates were significantly higher in those who received cetuximab in conjunction with chemotherapy (57 versus 40 percent), as was median PFS and OS (median 23.5 versus 20 months) [
         <a href="#rid112">
          112
         </a>
         ]. Adverse effects that were more frequent with cetuximab were grade 3 or 4 diarrhea (16 versus 11 percent), skin toxicity (19.7 versus 0.2 percent), and infusion reactions (2.5 versus 0 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         While there are no randomized trials in the first-line setting, the safety and efficacy of adding
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         to
         <strong>
         </strong>
         first line FOLFIRI has been shown in two single arm phase II trials [
         <a href="#rid113">
          113,114
         </a>
         ]. Panitumumab is indicated for first-line therapy in combination with
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         plus short-term infusional FU and LV (FOLFOX). However, panitumumab can be safely and acceptably combined with either an irinotecan- or oxaliplatin-based regimen in patients with
         <em>
          RAS and BRAF
         </em>
         wild-type tumors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Plus
         </strong>
         <strong>
          oxaliplatin
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In contrast to
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         , the benefit of adding
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         or
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         to a first-line oxaliplatin-based regimen is less certain. The data are mixed, with two trials suggesting benefit for combined therapy [
         <a href="#rid115">
          115,116
         </a>
         ], but four others suggesting a lack of benefit or even detrimental outcomes:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          MRC COIN trial
         </strong>
         – United Kingdom MRC COIN trial, which compared first-line FOLFOX/CAPOX with or without
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         in 1630 patients with mCRC, demonstrated a modest improvement in response rate from the addition of cetuximab in the 729 patients with
         <em>
          KRAS
         </em>
         wild-type tumors (64 versus 57 percent), but there was no significant improvement in PFS (8.6 months in both groups) [
         <a href="#rid117">
          117
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          NORDIC VII
         </strong>
         – Likewise, the NORDIC VII trial indicated a lack of benefit from the addition of
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         to a bolus FU/LV/
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         (FLOX) regimen in 571 patients with mCRC, even when the 348 patients with
         <em>
          KRAS
         </em>
         wild-type tumors were analyzed separately [
         <a href="#rid118">
          118
         </a>
         ]. These and other data support the view that the addition of EGFR inhibitor to oxaliplatin-based regimens in which noninfusional fluoropyrimidines were used has not resulted in benefit [
         <a href="#rid117">
          117
         </a>
         ].
         <strong>
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          EPOC
         </strong>
         – The randomized New EPOC trial of FOLFOX with or without
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         for patients with potentially resectable isolated colorectal cancer liver metastases suggested an
         <strong>
          inferior
         </strong>
         outcome with the addition of cetuximab [
         <a href="#rid119">
          119,120
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A PFS benefit for adding
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         to FOLFOX was shown in the phase III PRIME trial (median PFS 9.6 versus 8 months) [
         <a href="#rid121">
          121
         </a>
         ]; a later exploratory analysis also suggested a modest survival benefit at a median follow-up of 80 weeks (HR for death 0.83, 95% CI 0.70-0.98) [
         <a href="#rid122">
          122
         </a>
         ]. However, survival was impaired in patients with exon 2
         <em>
          KRAS
         </em>
         -mutant mCRC who received combined therapy. Furthermore, in a later analysis, 108 patients (17 percent) without
         <em>
          KRAS
         </em>
         mutations in exon 2 had other
         <em>
          RAS
         </em>
         mutations in
         <em>
          KRAS
         </em>
         exons 3 and 4 and in
         <em>
          NRAS
         </em>
         exons 2, 3, and 4 [
         <a href="#rid123">
          123
         </a>
         ]. These additional mutations predicted a lack of response to panitumumab, and in fact, their presence was associated with inferior PFS and OS in patients receiving panitumumab plus FOLFOX compared with FOLFOX alone.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with potentially resectable liver metastases
         </strong>
         – In particular, the advisability of combining
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         (or
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         ) with an oxaliplatin-based regimen in patients with potentially resectable colorectal cancer liver metastases continues to be debated, with disparate results from published trials:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The randomized phase II CELIM trial of
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         plus either FOLFIRI or FOLFOX in patients with initially unresectable colorectal cancer liver metastases showed that the chemotherapy backbone did not matter [
         <a href="#rid124">
          124
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         On the other hand, as noted above, the randomized New EPOC trial of FOLFOX with or without
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         for patients with potentially resectable isolated colorectal cancer liver metastases suggested an
         <strong>
          inferior
         </strong>
         outcome with the addition of cetuximab [
         <a href="#rid119">
          119,120
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         This subject is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Regimen choice'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Plus
         </strong>
         <strong>
          oxaliplatin
         </strong>
         <strong>
          and
         </strong>
         <strong>
          irinotecan
         </strong>
         – Whether there is benefit to adding
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         or
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         to triplet combination regimens such as FOLFOXIRI  (
         <a class="graphic graphic_table graphicRef70559" href="/z/d/graphic/70559.html" rel="external">
          table 2
         </a>
         ) is unclear, as the data are mixed [
         <a href="#rid24">
          24,125-127
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         High objective response rates (&gt;70 percent), and high rates of secondary complete (R0) metastasectomy are reported with combinations of
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         plus FOLFOXIRI, but there are no randomized trials comparing this strategy versus FOLFOXIRI alone or cetuximab plus a chemotherapy backbone doublet such as FOLFOX [
         <a href="#rid125">
          125,126
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The randomized phase II VOLFI trial reported a very high objective response rate (87 versus 61 percent) and a higher secondary complete (R0) metastasectomy rate (33 versus 12 percent) for initial FOLFOXIRI plus
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         , albeit with similar PFS and higher rates of grade ≥3 toxicity (81 versus 67 percent) when compared with FOLFOXIRI alone [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         However, a benefit for
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         plus the triplet regimen was not shown relative to FOLFOX plus panitumumab in the later phase III TRIPLETE trial conducted by the same investigators [
         <a href="#rid127">
          127
         </a>
         ]. Intensification of the chemotherapy backbone did not provide a better objective response rate (73 versus 76 percent), or secondary complete (R0) metastasectomy resection rate (25 versus 29 percent), or median PFS (12.7 versus 12.3 months) but it did substantially increase grade ≥3 toxicity, especially neutropenia (32 versus 20 percent) and diarrhea (23 versus 7 percent). There were three treatment-related deaths in the intensified chemotherapy arm versus none in the FOLFOX group.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A triplet regimen such as FOLFOXIRI in combination with an EGFR agent could be considered an alternative to initial doublet therapy plus an EGFR inhibitor for first-line therapy in selected patients for whom a more aggressive initial approach is chosen (eg, younger age, high tumor load, or highly symptomatic disease), as long as they are able to tolerate intensive therapy. Given the very high response rate for FOLFOXIRI plus
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         (87 percent) in the phase II randomized VOLFI trial [
         <a href="#rid24">
          24
         </a>
         ], we consider this to be a reasonable regimen for patients who are able to tolerate it and who require a strong anatomic response to be considered for hepatic resection. (See
         <a class="local">
          'Three- versus two-drug combinations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, as noted above, the use of combination regimens with
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         and an EGFR inhibitor in patients with potentially resectable colorectal cancer liver metastases continues to be debated, and many clinicians would avoid this combination in this setting.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4127866647">
         <span class="h5">
          Adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common adverse effects associated with
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         and
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         are weakness, malaise, an acneiform rash, nausea, electrolyte disorders, and, with cetuximab, infusion reactions.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infusion reactions
         </strong>
         – Infusion reactions occur in up to 25 percent of patients treated with
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         , and rates are highest in some areas of the middle southeastern United States. The majority of these reactions are the result of pre-existing IgE antibodies to galactose-alpha-1,3-galactose which cross-react with cetuximab. Most reactions are severe, and 90 percent occur after the first infusion, most within three hours. Premedication with an H1 receptor antagonist and a glucocorticoid is recommended, and drug infusion should not exceed 5 mL/minute.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who develop a severe reaction to
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         , switching to
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         is a better alternative to proceeding with cetuximab desensitization given what appears to be very similar efficacy between agents. (See
         <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">
          "Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Cetuximab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The risk of infusion reactions with
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         is lower than with
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         (4 percent overall, with 1 percent severe). Given the low rates of infusion reactions, routine premedication is not recommended prior to panitumumab infusion. The lower rate of infusion reactions provides a rationale for choosing panitumumab over cetuximab, particularly in high-risk geographic regions such as the middle southeastern United States. (See
         <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">
          "Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Panitumumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cutaneous and ocular toxicity
         </strong>
         – As with all agents that target the EGFR, skin reactions are frequent and may be severe in patients treated with
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         or
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         (
         <a class="graphic graphic_table graphicRef57215" href="/z/d/graphic/57215.html" rel="external">
          table 9
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most common side effect is an acneiform type rash  (
         <a class="graphic graphic_picture graphicRef55753" href="/z/d/graphic/55753.html" rel="external">
          picture 1
         </a>
         ), which occurs in up to two-thirds of treated patients, and may impact quality of life. Grading of the severity of the acneiform eruption that is most typical of this class of agents, management of cutaneous toxicity, and the use of prophylactic systemic antibiotics are addressed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/15764.html" rel="external">
          "Acneiform eruption secondary to epidermal growth factor receptor (EGFR) and MEK inhibitors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Rash severity appears to correlate with better outcomes [
         <a href="#rid128">
          128-131
         </a>
         ]. A report from the EVEREST trial suggests that
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         dose escalation (by 50 mg/m
         <sup>
          2
         </sup>
         every two weeks, up to 500 mg/m
         <sup>
          2
         </sup>
         weekly) is safe and increases response rates in patients who have no or a mild skin reaction within three weeks of starting therapy [
         <a href="#rid132">
          132
         </a>
         ]. The response rate among patients with ≤grade 1 skin toxicity  (
         <a class="graphic graphic_table graphicRef67786" href="/z/d/graphic/67786.html" rel="external">
          table 10
         </a>
         ) who were randomized to dose escalation was 30 versus 16 percent in a concurrently randomized group continuing standard dose therapy, and there was also an improvement in disease control rate (70 versus 58 percent) but no indication of improved OS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pruritus is particularly common in patients treated with
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         . In a systematic review, the incidence of any grade pruritus was 55 percent with panitumumab (2.6 percent high-grade) and 18 percent with
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         (2.1 percent severe) [
         <a href="#rid133">
          133
         </a>
         ]. Management includes patient education and topical agents (emollients, corticosteroids, anesthetics,
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         , menthol); for highly symptomatic patients, oral antihistamines, anticonvulsants, antidepressants, and possibly
         <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">
          aprepitant
         </a>
         may be helpful. An overview of management of pruritus is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5576.html" rel="external">
          "Pruritus: Therapies for localized pruritus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Multiple ocular toxicities are reported with both
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         and
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/96203.html" rel="external">
          "Ocular side effects of systemically administered chemotherapy", section on 'Epidermal growth factor receptor (EGFR) inhibitor'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Electrolyte disorders
         </strong>
         –
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          Cetuximab
         </a>
         and
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         both cause a magnesium-wasting syndrome, which, in one report, affected 22 percent of 154 patients treated with cetuximab [
         <a href="#rid134">
          134,135
         </a>
         ]. Hypomagnesemia may be more prominent in patients receiving concomitant treatment with
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         [
         <a href="#rid136">
          136
         </a>
         ]. In addition, hypokalemia is also reported (incidence 8 percent in a meta-analysis of patients treated with cetuximab [
         <a href="#rid137">
          137
         </a>
         ]). Hypomagnesemia may lead to secondary hypocalcemia. Serum levels of magnesium, potassium, and calcium should be monitored periodically during and for at least eight weeks following therapy. (See
         <a class="medical medical_review" href="/z/d/html/114914.html" rel="external">
          "Nephrotoxicity of molecularly targeted agents and immunotherapy", section on 'Anti-EGFR monoclonal antibodies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/848.html" rel="external">
          "Hypomagnesemia: Clinical manifestations of magnesium depletion", section on 'Calcium metabolism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H35">
         <span class="h5">
          EGFR inhibitors versus bevacizumab and the influence of tumor sidedness
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with previously untreated mCRC, the site of the primary tumor influences the choice of biologic agent added to chemotherapy. Analyses of randomized trials suggest that right-sided tumors, including those that are
         <em>
          RAS
         </em>
         and
         <em>
          BRAF
         </em>
         wild-type, derive relatively more benefit from treatment with
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         whereas left-sided tumors that are
         <em>
          RAS
         </em>
         and
         <em>
          BRAF
         </em>
         -wildtype derive relatively more benefit from treatment with EGFR inhibitors (eg,
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         ) [
         <a href="#rid138">
          138-145
         </a>
         ]. Our approach to selecting the biologic agent to combine with chemotherapy is generally consistent with clinical guidelines from the NCCN, ESMO, and ASCO [
         <a href="#rid10">
          10-12
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           RAS
          </em>
         </strong>
         <strong>
          /
         </strong>
         <strong>
          <em>
           BRAF
          </em>
         </strong>
         <strong>
          wild-type right-sided tumors
         </strong>
         – For patients with
         <em>
          RAS
         </em>
         and
         <em>
          BRAF
         </em>
         wild-type mCRC and a right-sided primary tumor (ie, proximal to the splenic flexure [
         <a href="#rid146">
          146
         </a>
         ]), we suggest adding
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         rather than an EGFR inhibitor to chemotherapy as initial treatment. For those with a contraindication to bevacizumab, we use chemotherapy alone rather than adding an EGFR inhibitor to chemotherapy, as the latter approach does not confer an OS benefit. Contraindications to bevacizumab therapy are discussed separately. (See
         <a class="local">
          'Contraindications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           RAS
          </em>
         </strong>
         <strong>
          /
         </strong>
         <strong>
          <em>
           BRAF
          </em>
         </strong>
         <strong>
          wild-type left-sided tumors
         </strong>
         – For patients with
         <em>
          RAS
         </em>
         or
         <em>
          BRAF
         </em>
         wild-type mCRC and a left-sided primary tumor (ie, located at or distal to the splenic flexure [
         <a href="#rid146">
          146
         </a>
         ]), we suggest adding an EGFR inhibitor (
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         or
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         ) rather than
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         to chemotherapy as initial treatment. For those patients who wish to avoid the toxicities associated with EGFR inhibitors (eg, diarrhea and rash) for quality of life, the addition of bevacizumab to chemotherapy is an alternative option. However, most studies suggest inferior survival outcomes for bevacizumab compared with EGFR inhibitors in this population.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cetuximab
         </strong>
         <strong>
          versus
         </strong>
         <strong>
          bevacizumab
         </strong>
         – A pooled analysis of twelve randomized trials consisting of 9277 patients with previously untreated mCRC included a subgroup of 555 patients with
         <em>
          KRAS
         </em>
         wild-type tumors. Among those with right-sided
         <em>
          KRAS
         </em>
         wild-type tumors, an OS benefit was demonstrated for treatment regimens that included
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         versus regimens that included
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         [
         <a href="#rid144">
          144
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For the 555 patients with
         <em>
          KRAS
         </em>
         wild-type tumors, compared with
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         plus chemotherapy,
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         plus chemotherapy improved OS among the 300 patients with right-sided tumors (median 26 versus 12.5 months, HR 1.89, 95% CI 1.33-2.67) but not the 255 patients with left-sided tumors (median 24.6 versus 25.5 months, HR 1.10, 95% CI 0.77-1.56).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with a right-sided tumor who are ineligible for
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         may be offered chemotherapy alone, as the addition of
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         did not confer an OS benefit in this study. Among patients with a
         <em>
          KRAS
         </em>
         wild-type right-sided tumor, the addition of cetuximab to chemotherapy did not improve OS (median 12 versus 14.8 months, HR 1.26, 95% CI 0.98-1.63) or PFS (median 7.2 months each, HR 1.02, 95% CI 0.77-1.34).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For
         <em>
          RAS
         </em>
         wild-type left-sided tumors, the benefits of initial therapy with cetuximab-based regimens were seen in a meta-analysis of three randomized trials directly comparing chemotherapy plus either
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         or
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         [
         <a href="#rid142">
          142
         </a>
         ]. For patients with
         <em>
          RAS
         </em>
         wild-type left-sided colorectal tumors, treatment that included an EGFR inhibitor conferred a greater overall survival benefit than treatment than included a VEGF inhibitor (HR 0.71, 95% CI 0.58-0.85). In contrast, for patients with right-sided tumors, there was a non-statistically significant trend toward longer survival with bevacizumab-based therapy compared with other standard therapies (HR 1.3, 95% CI 0.979-1.74).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Panitumumab
         </strong>
         <strong>
          versus
         </strong>
         <strong>
          bevacizumab
         </strong>
         – In a phase III trial (PARADIGM), initial therapy with the EGFR inhibitor
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         plus chemotherapy conferred an OS benefit over
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         plus chemotherapy among all patients with mCRC as well as those with left-sided tumors [
         <a href="#rid147">
          147
         </a>
         ]. For patients with right-sided tumors, panitumumab plus chemotherapy demonstrated similar OS but lower PFS compared with bevacizumab plus chemotherapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In this study, 802 patients with chemotherapy-naïve
         <em>
          RAS
         </em>
         wild-type mCRC were randomly assigned to mFOLFOX6 plus either
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         or
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         [
         <a href="#rid147">
          147,148
         </a>
         ]. The study included 604 patients with left-sided tumors, 187 patients with right-sided tumors, and 11 patients with tumors on both sides. At median follow-up of 61 months, compared with bevacizumab plus chemotherapy, panitumumab plus chemotherapy resulted in the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Left-sided tumors
         </strong>
         – Improved OS (median OS 38 versus 34 months, HR 0.82, 96% CI 0.68-0.99), similar PFS (median PFS 13 versus 11 months, HR 0.86, 95% CI 0.70-1.10), and higher objective response rates (80 versus 69 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Entire study population
         </strong>
         – Improved OS (median OS 36 versus 31 months, HR 0.84, 95% CI 0.72-0.98) and similar PFS (median PFS 12 vs 11 months, HR 1.05, 95% CI 0.90-1.24). Objective response rates for chemotherapy plus either
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         or
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         were 75 and 67 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Right-sided tumors
         </strong>
         – Similar OS (median OS 20 versus 23 months, HR 1.09, 95% CI 0.79-1.51) but lower PFS (median PFS 7 versus 9 months, HR 1.43, 95% CI, 1.03-1.97). Objective response rates for chemotherapy plus either
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         or
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         were 55 and 63 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Toxicity profiles were consistent with those known for each agent. Compared with
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         had higher grade ≥3 toxicity rates of acneiform rash (17 versus 0 percent) stomatitis (7 versus 2 percent), diarrhea (6 versus 3 percent) and hypomagnesemia (8 versus 0 percent). In contrast, compared with panitumumab, bevacizumab had higher rates of grade ≥3 hypertension (6 versus &lt;1 percent) and epistaxis of any grade (20 versus 3 percent). The rate of treatment discontinuation due to adverse events for the panitumumab- and bevacizumab-treated groups were 24 and 18 percent, respectively.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1140842442">
         <span class="h4">
          RAS or BRAF mutant tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with
         <em>
          RAS
         </em>
         mutated mCRC and any primary tumor site location who are treated with a biologic agent, we recommend the addition of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         rather than an EGFR inhibitor to chemotherapy. Patients who are ineligible for bevacizumab may be offered chemotherapy alone. EGFR inhibitors are not used to treat
         <em>
          RAS
         </em>
         mutated mCRC since such tumors are resistant to these agents. Further details are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'RAS'
         </a>
         .)
        </p>
        <p>
         A pooled analysis of twelve randomized trials consisting of 9277 patients with previously untreated mCRC included a subgroup of patients with 522
         <em>
          KRAS
         </em>
         mutant tumors [
         <a href="#rid144">
          144
         </a>
         ]. In this subgroup, compared with
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         plus chemotherapy,
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         plus chemotherapy demonstrated inferior OS for both patients with left-sided (median OS 13.1 versus 24.8 months, HR 2.09, 95% CI 1.40-3.12) and right-sided (median OS 15.9 versus 26.1 months, HR 1.84, 95% CI 1.37-2.47) tumors.
        </p>
        <p>
         Although such data are limited for
         <em>
          BRAF
         </em>
         mutant tumors [
         <a href="#rid149">
          149,150
         </a>
         ], we extrapolate a similar approach using studies from
         <em>
          KRAS
         </em>
         mutant tumors, given the shared biologic signaling pathway. Furthermore, data suggest no benefit for EGFR inhibitors in
         <em>
          BRAF
         </em>
         mutant cancers. (See
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'BRAF mutations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1542090753">
         <span class="h4">
          Dual antibody therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dual antibody therapy (simultaneously targeting both VEGF and EGFR) cannot be recommended for first-line therapy of mCRC.
        </p>
        <p>
         The results of two trials suggest worse outcomes with dual antibody therapy when used in the first-line setting:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The PACCE trial tested the addition of
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         to standard first-line oxaliplatin-based (n = 823) or irinotecan-based therapy (n = 230) plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         [
         <a href="#rid151">
          151
         </a>
         ]. Enrollment was halted after a preplanned interim analysis detected significantly inferior PFS in the panitumumab/bevacizumab group; median OS was also lower (19.4 versus 24.5 months).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The CAIRO2 trial studied first-line
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         plus CAPOX with or without
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         [
         <a href="#rid152">
          152
         </a>
         ]. PFS was significantly worse with dual antibody therapy. Even patients with wild-type KRAS tumors did not benefit from the addition of cetuximab.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H866022683">
         <span class="h4">
          Is there benefit from immunotherapy?
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although a small subset of mCRC have deficient mismatch repair and might be eligible for upfront immunotherapy as an alternative to chemotherapy, the majority are proficient in mismatch repair (pMMR) and a benefit for immune checkpoint inhibitor immunotherapy without high levels of tumor mutational burden is not yet established. (See
         <a class="local">
          'Patients with deficient DNA mismatch repair/microsatellite unstable tumors'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'MMR-proficient tumors with high tumor mutational burden'
         </a>
         .)
        </p>
        <p>
         Given that pMMR tumors are typically characterized by an immune-excluded microenvironment, with absent or inactive CD8 T-cell lymphocytes, and diminished expression of immune checkpoint proteins on the tumor cells [
         <a href="#rid153">
          153,154
         </a>
         ], trials are ongoing to attempt to increase cellular immunogenicity by combining checkpoint inhibitors with antitumoral agents with immunomodulatory properties [
         <a href="#rid155">
          155-157
         </a>
         ]. However, whether there is benefit for combined therapy in this setting remains an open research question.
        </p>
        <p class="headingAnchor" id="H553389544">
         <span class="h3">
          Duration of initial chemotherapy
         </span>
        </p>
        <p class="headingAnchor" id="H553389556">
         <span class="h4">
          Oxaliplatin-based regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oxaliplatin-related neurotoxicity limits the amount of effective therapy that can be administered. (See
         <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">
          "Overview of neurologic complications of platinum-based chemotherapy", section on 'Cumulative sensory neuropathy'
         </a>
         .)
        </p>
        <p>
         Whether long-term neurotoxicity can by mitigated by intermittent oxaliplatin-free intervals has been addressed in multiple randomized trials. When FOLFOX with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         is used for first-line therapy, the available data suggest that it is reasonable to discontinue
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         temporarily while maintaining a fluoropyrimidine with or without bevacizumab [
         <a href="#rid158">
          158
         </a>
         ]. This approach is consistent with consensus-based guidelines from ESMO [
         <a href="#rid10">
          10
         </a>
         ]. For patients initially treated with an agent targeting EGFR,
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         alone is an acceptable alternative for maintenance treatment in patients initially treated with a cetuximab-containing regimen, but for patients initially treated with a panitumumab-containing regimen,
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         plus LV-modulated FU is preferred over panitumumab alone.
        </p>
        <p>
         In both of these settings,
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         continuation is also an option if the patient is responding to therapy and there is no evidence of neuropathy. Another option is a complete break from chemotherapy. Although early data suggested inferior outcomes, compared with continued chemotherapy, with an oxaliplatin-free regimen, these results have been called into question by a more recent meta-analysis. We reserve this approach for patients with small volume disease.
        </p>
        <p>
         The subjects of oxaliplatin-free intervals and intermittent versus continuous therapy are addressed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'Patients receiving oxaliplatin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H553389590">
         <span class="h4">
          Irinotecan-based regimens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Though cumulative neurotoxicity is not an issue with irinotecan-based regimens, most patients experience some cumulative toxicity albeit that may not require dose modification. The available data suggest similar overall outcomes (PFS and OS) whether or not the regimen is administered continuously until progression or toxicity, or in "two months on/two months off" intervals. These data are discussed elsewhere. We consider it reasonable to extrapolate data on maintenance therapy and chemotherapy-free intervals to patients treated with first-line FOLFIRI. (See
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'Continuous versus intermittent therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1619026613">
         <span class="h4">
          FOLFOXIRI
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who start on triplet therapy should proceed with this as induction for a three to four month period as per the TRIBE clinical trials [
         <a href="#rid17">
          17,20
         </a>
         ], and then transition to a non-oxaliplatin-containing maintenance chemotherapy regimen (FU plus
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         with or without
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         ). (See
         <a class="local">
          'Three- versus two-drug combinations'
         </a>
         above.)
        </p>
        <p>
         In practice, we try to treat to maximal response (as long as triplet therapy is tolerated) before decreasing to a maintenance regimen.
        </p>
        <p class="headingAnchor" id="H3837317327">
         <span class="h2">
          Not candidates for intensive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients without MMR deficiency who are not candidates for an intensive first-line standard-dose oxaliplatin- or irinotecan-based regimen because of age, poor performance status or associated comorbidity, but who are fit enough to tolerate some form of systemic therapy, options include dose-reduced FOLFOX, a fluoropyrimidine alone or, for patients with no contraindication, a fluoropyrimidine plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         . Nonchemotherapy options can also be considered for patients with
         <em>
          RAS/BRAF
         </em>
         wild-type cancers (
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         or
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         ) and HER2-targeted therapy can be considered for the small proportion of patients whose colorectal cancers express high levels of HER2 expression, although there are no data specifically in the first-line setting. Consensus-based guidelines from the NCCN include HER2-targeted therapy as a first line option for patients with metastatic colorectal cancer who are unable to tolerate intensive therapy [
         <a href="#rid11">
          11
         </a>
         ]. Individuals with a poor PS (eg, Eastern Cooperative Oncology Group [ECOG] PS ≥2  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 11
         </a>
         ), Karnofsky PS &lt;60  (
         <a class="graphic graphic_table graphicRef62939" href="/z/d/graphic/62939.html" rel="external">
          table 12
         </a>
         )) usually tolerate chemotherapy poorly and have a poor short-term prognosis. For most patients, supportive care should be emphasized. However, some selected patients with mCRC who have a PS of ≥2 can be considered for trial of chemotherapy, particularly if their PS decline is cancer related. This subject is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2512.html" rel="external">
          "Therapy for metastatic colorectal cancer in older adult patients and those with a poor performance status", section on 'Less fit patients with an ECOG PS 0 or 1'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2512.html" rel="external">
          "Therapy for metastatic colorectal cancer in older adult patients and those with a poor performance status", section on 'Frail, significant functional impairment, poor performance status'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3835316973">
         <span class="h1">
          PATIENTS WITH DEFICIENT DNA MISMATCH REPAIR/MICROSATELLITE UNSTABLE TUMORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with nonoperable mCRC that is deficient in deficient mismatch repair (dMMR), we suggest first-line
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         monotherapy rather than cytotoxic chemotherapy. Another option for immune checkpoint inhibitor therapy is
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         with or without
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         . If a first-line immunotherapy approach is chosen, patients should be followed closely for the first 10 weeks to assess response and rule out early progression. For patients with high tumor burden, it is also reasonable to consider upfront chemotherapy, either alone or with pembrolizumab, to mitigate this risk of primary progressive disease. Whether the combination of cytotoxic chemotherapy plus immunotherapy is superior to immunotherapy alone is unknown and currently the focus of phase III trials.
        </p>
        <p>
         Approximately 3.5 to 6.5 percent of stage IV CRCs have deficiency in dMMR enzymes, the biologic footprint of which is high microsatellite instability (MSI-H). Cancers with dMMR/MSI-H appear to be uniquely susceptible to inhibition of immune checkpoints, tolerance mechanisms that suppress the body's immune response to self-antigens in order to minimize autoimmune disease, which may also serve to blunt the immune response to tumor antigens in vivo. (See
         <a class="medical medical_review" href="/z/d/html/2485.html" rel="external">
          "Molecular genetics of colorectal cancer", section on 'Mismatch repair genes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/120646.html" rel="external">
          "Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Biology of mismatch repair and tumor mutational burden'
         </a>
         .)
        </p>
        <p>
         Most of the data on benefits of immune checkpoint inhibitor immunotherapy are in previously treated patients, after failure of conventional cytotoxic chemotherapy. (See
         <a class="medical medical_review" href="/z/d/html/129349.html" rel="external">
          "Systemic therapy for nonoperable metastatic colorectal cancer: Approach to later lines of systemic therapy", section on 'Microsatellite unstable/deficient mismatch repair tumors'
         </a>
         .)
        </p>
        <p>
         However, results from the KEYNOTE-177 trial suggest that first-line
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         , a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) pathway, offers better outcomes than first-line chemotherapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          Pembrolizumab
         </a>
         <strong>
          monotherapy
         </strong>
         – In the KEYNOTE-177 (KN-177) trial, first-line pembrolizumab monotherapy (200 mg every three weeks,  (
         <a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">
          table 13
         </a>
         )) was compared with conventional chemotherapy with either an oxaliplatin- or irinotecan-containing regimen in 307 patients with dMMR/MSI-H tumors [
         <a href="#rid159">
          159
         </a>
         ]. Pembrolizumab was superior to upfront chemotherapy in terms of progression-free survival (median 16.5 versus 8.2 months), objective response rate (44 versus 33 percent), and duration of response. Among patients with an overall response, 83 percent in the pembrolizumab group versus 35 percent of those in the chemotherapy group had ongoing responses at 24 months. Pembrolizumab was also associated with better tolerability (grade 3 to 5 adverse reaction rates 22 versus 66 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Two subsequent analyses of the KN-177 trial have addressed quality of life (QOL) and overall survival (OS):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In one report, patients receiving
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         had clinically meaningful improvements in their health-related QOL when compared with those receiving chemotherapy [
         <a href="#rid160">
          160
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the final analysis of OS data, there was a trend toward reduced risk of death that favored
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         (HR 0.74, 95% CI 0.53-1.03), but interpretation was complicated by the fact that 60 percent of the patients treated with first-line chemotherapy crossed over to pembrolizumab at some point, either on or off protocol [
         <a href="#rid161">
          161
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Notably, more patients in the
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         arm had progressive disease as their best response (30 versus 12 percent), and if this approach is chosen, patients should be followed closely for the first 10 weeks to assess response, especially those with a high tumor burden or rapidly progressive disease. One potential alternative in these settings is to combine immunotherapy and chemotherapy or start with cytotoxic chemotherapy, followed by maintenance immunotherapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Individuals treated with immune checkpoint inhibitors for any cancer, including dMMR/MSI-H mCRC, can have pseudoprogression within the first several months of treatment [
         <a href="#rid162">
          162
         </a>
         ], and response criteria specifically geared toward these drugs (ie, immune-modified RECIST  (
         <a class="graphic graphic_table graphicRef116649" href="/z/d/graphic/116649.html" rel="external">
          table 14
         </a>
         )) should be used. (See
         <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">
          "Principles of cancer immunotherapy", section on 'Immunotherapy response criteria'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Largely based upon these data, in June 2020, the US Food and Drug Administration (FDA) approved
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer [
         <a href="#rid163">
          163
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A year 2022 guideline on management of mCRC from ASCO concluded that based on the results of the KN-177 trial,
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         should be offered as first-line therapy to patients with dMMR mCRC (evidence-based, benefits outweigh harms, evidence quality moderate, strength of recommendation: strong) [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          Nivolumab
         </a>
         <strong>
          plus
         </strong>
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         – Additional data on first-line immunotherapy using nivolumab (a different anti-PD-1 antibody) plus ipilimumab (which targets a different immune checkpoint, cytotoxic T-lymphocyte associated antigen 4) are available from the phase II Checkmate 142 trial [
         <a href="#rid164">
          164
         </a>
         ]. Forty-five patients with dMMR mCRC and no prior treatment in the metastatic disease setting received nivolumab 3 mg/kg every two weeks plus low dose ipilimumab (1 mg/kg every six weeks) with both drugs continued until disease progression or discontinuation for other reason. The median overall response rate was 69 percent by investigator assessment and 62 percent by blinded central review; six patients (13 percent) had progressive disease as the best initial response. The median duration of response was not reached, and at data cutoff (median duration of follow-up 29 months) 23 of 31 responders (74 percent ) had ongoing response. Even while off treatment, further tumor shrinkage was observed in some patients. Treatment-related grade 3 or 4 toxicities were reported in only 22 percent of patients, and only six discontinued therapy because of a treatment-related adverse event. Whether these results are better than can be achieved with
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         monotherapy will require a randomized trial.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Updated consensus-based guidelines from the National Comprehensive Cancer Network now include
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         with or without
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         as options for first-line therapy of dMMR/MSI-H mCRC, but
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         monotherapy is preferred.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2048323184">
         <span class="h1">
          ISSUES RELATED TO VITAMIN D
         </span>
         <span class="headingEndMark">
          —
         </span>
         An association between vitamin D levels and prognosis of mCRC has been suggested [
         <a href="#rid165">
          165-167
         </a>
         ]. In a report of a retrospective analysis of 1041 patients with mCRC who were treated on the phase III CALGB (Alliance) 80405 trial comparing chemotherapy plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         , or both, those in the highest quintile of vitamin D levels had a significantly improved overall survival (OS) compared with those in the lowest quintile (median OS 33 versus 25 months, multivariate adjusted HR 0.66, 95% CI 0.53-0.83) [
         <a href="#rid167">
          167
         </a>
         ]. One concern that has been raised is that higher vitamin D levels may be acting as a surrogate for other healthy behaviors or biologically more favorable disease.
        </p>
        <p>
         The issue of whether higher levels of vitamin D supplementation can improve prognosis in conjunction with chemotherapy was addressed in the randomized, phase II SUNSHINE trial, in which 139 patients with previously untreated mCRC who were receiving first-line chemotherapy were randomly assigned to high-dose
         <a class="drug drug_general" data-topicid="10117" href="/z/d/drug information/10117.html" rel="external">
          vitamin D3
         </a>
         (8000 international units [IU] daily for two weeks followed by 4000 IU daily) or standard-dose vitamin D3 (400 IU per day). The group receiving high-dose vitamin D experienced a statistically insignificant two-month increase in median PFS (13 versus 11 months, one-sided p value 0.07) [
         <a href="#rid168">
          168
         </a>
         ]. However, in adjusted analysis, patients in the high-dose group were less likely to experience progression or death at any point during the median follow-up of 22 months (adjusted HR 0.64, one-sided 95% CI 0-0.9). There was no indication of an OS benefit for high-dose vitamin D. Larger confirmatory phase III trials are needed to evaluate these preliminary findings. (See
         <a class="medical medical_review" href="/z/d/html/13915.html" rel="external">
          "Vitamin D and extraskeletal health", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         Given the benefits of vitamin D repletion in terms of skeletal health and the possibility of better cancer-related outcomes, it seems reasonable to test serum vitamin D levels in patients with newly diagnosed mCRC and to replete those with low levels (serum 25[OH]D &lt;20 ng/mL [50 nmol/L]). (See
         <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">
          "Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3554637184">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115274.html" rel="external">
          "Society guideline links: Colorectal cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10071857">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15412.html" rel="external">
          "Patient education: Colon and rectal cancer (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/874.html" rel="external">
          "Patient education: Colon and rectal cancer (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/860.html" rel="external">
          "Patient education: Colorectal cancer treatment; metastatic cancer (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H43">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         –
         <strong>
         </strong>
         The majority of patients with metastatic colorectal cancer (mCRC) cannot be cured. The goals of palliative chemotherapy are to relieve symptoms, improve quality of life, and prolong survival. The best way to combine and sequence all of the active agents is not yet established. Exposure to all active drugs is more important than specific sequence. (See
         <a class="local">
          'Overview of the therapeutic approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Biomarker testing
         </strong>
         – Biomarker expression drives therapeutic decision-making, and gene profiling of tumor tissue should be undertaken as quickly as possible after diagnosis. (See
         <a class="local">
          'Predictive biomarkers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment approach
         </strong>
         – Our general approach to initial chemotherapy for nonoperable mCRC is outlined in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef109247" href="/z/d/graphic/109247.html" rel="external">
          algorithm 1
         </a>
         ) and summarized below. Specific recommendations for patients with hepatic metastases who are potential candidates for resection are provided elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">
          "Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with dMMR tumors
         </strong>
         – For patients with mCRC that is deficient in DNA mismatch repair (dMMR), we suggest first-line
         <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">
          pembrolizumab
         </a>
         rather than cytotoxic chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Other options for immunotherapy include
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         with or without
         <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">
          ipilimumab
         </a>
         . If upfront immunotherapy is chosen, patients should be followed closely for the first 10 weeks to assess response. (See
         <a class="local">
          'Patients with deficient DNA mismatch repair/microsatellite unstable tumors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients without dMMR who are eligible for intensive therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chemotherapy backbone (triplet therapy)
         </strong>
         –
         <strong>
         </strong>
         For patients with a good performance status (PS) who are able to tolerate intensive therapy, and have a large tumor volume, we suggest triplet therapy with FOLFOXIRI (
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         and
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         with
         <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">
          fluorouracil
         </a>
         [FU]/
         <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">
          leucovorin
         </a>
         [LV]  (
         <a class="graphic graphic_table graphicRef70559" href="/z/d/graphic/70559.html" rel="external">
          table 2
         </a>
         )), rather than initial doublet therapy containing either oxaliplatin or irinotecan (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). If chosen, the triplet regimen should be restricted to an induction period of three to six months, followed by maintenance treatment with a fluoropyrimidine alone. (See
         <a class="local">
          'Three- versus two-drug combinations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chemotherapy backbone (doublet therapy)
         </strong>
         – For other patients, we suggest a chemotherapy doublet (FOLFOX [
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
         plus LV plus infusional FU,  (
         <a class="graphic graphic_table graphicRef50132" href="/z/d/graphic/50132.html" rel="external">
          table 5
         </a>
         )], XELOX [oxaliplatin plus
         <a class="drug drug_general" data-topicid="8839" href="/z/d/drug information/8839.html" rel="external">
          capecitabine
         </a>
         ; also known as CAPOX  (
         <a class="graphic graphic_table graphicRef61781" href="/z/d/graphic/61781.html" rel="external">
          table 6
         </a>
         )], or FOLFIRI [
         <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">
          irinotecan
         </a>
         plus LV and short-term infusional FU])  (
         <a class="graphic graphic_table graphicRef64504" href="/z/d/graphic/64504.html" rel="external">
          table 3
         </a>
         ) rather than sequential use of single agents or an initial triplet regimen containing both oxaliplatin and irinotecan (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Initial doublet combinations versus sequential single agents'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/85679.html" rel="external">
          "Treatment protocols for small and large bowel cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Selecting between FOLFOX versus FOLFIRI
         </strong>
         – FOLFOX and FOLFIRI have similar first-line efficacy, and the choice should be based on the expected toxicity. FOLFIRI  (
         <a class="graphic graphic_table graphicRef76300" href="/z/d/graphic/76300.html" rel="external">
          table 15
         </a>
         ) is preferred for patients who received an adjuvant oxaliplatin-based regimen within the prior 12 months. (See
         <a class="local">
          'Treatment-related toxicity'
         </a>
         above and
         <a class="local">
          'FOLFOX versus FOLFIRI'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Biologic agent
         </strong>
         – The potential benefits of adding a biologic agent to the chemotherapy backbone must be weighed against potential adverse effects. If this approach is chosen, we select the biologic agent (
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         or an EGFR inhibitor) based on several factors, including
         <em>
          RAS
         </em>
         /
         <em>
          BRAF
         </em>
         mutation status, primary tumor site, and eligibility for bevacizumab (See
         <a class="local">
          'Role of biologics'
         </a>
         above.):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          <em>
           RAS
          </em>
         </strong>
         <strong>
          and
         </strong>
         <strong>
          <em>
           BRAF
          </em>
         </strong>
         <strong>
          wild-type, right-sided tumors
         </strong>
         – For patients with a
         <em>
          RAS
         </em>
         and
         <em>
          BRAF
         </em>
         wild-type CRC and a right-sided primary tumor (ie, proximal to the splenic flexure), we suggest adding
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         rather than an EGFR inhibitor to chemotherapy as initial treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For those with a contraindication to bevacizumab, we use chemotherapy alone rather than adding an EGFR inhibitor to chemotherapy. (See
         <a class="local">
          'EGFR inhibitors versus bevacizumab and the influence of tumor sidedness'
         </a>
         above and
         <a class="local">
          'Contraindications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          <em>
           RAS
          </em>
         </strong>
         <strong>
          and
         </strong>
         <strong>
          <em>
           BRAF
          </em>
         </strong>
         <strong>
          wild-type, left-sided tumors
         </strong>
         – For patients with
         <em>
          RAS
         </em>
         and
         <em>
          BRAF
         </em>
         wild-type mCRC and a left-sided primary (ie, located at or distal to the splenic flexure), we suggest adding an EGFR inhibitor (
         <a class="drug drug_general" data-topicid="9209" href="/z/d/drug information/9209.html" rel="external">
          cetuximab
         </a>
         or
         <a class="drug drug_general" data-topicid="10336" href="/z/d/drug information/10336.html" rel="external">
          panitumumab
         </a>
         ) rather than
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         to chemotherapy as initial treatment (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). For those patients who wish to avoid the toxicities associated with an EGFR inhibitor (ie, diarrhea and acneiform rash) for quality of life, the addition of bevacizumab to chemotherapy is an alternative option, although data suggest that survival outcomes are inferior. (See
         <a class="local">
          'EGFR inhibitors versus bevacizumab and the influence of tumor sidedness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          <em>
           RAS
          </em>
         </strong>
         <strong>
          or
         </strong>
         <strong>
          <em>
           BRAF
          </em>
         </strong>
         <strong>
          mutant tumors
         </strong>
         – For patients with
         <em>
          RAS
         </em>
         mutated mCRC and any primary tumor site, we recommend the addition of
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         rather than an EGFR inhibitor to chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). For patients with
         <em>
          BRAF
         </em>
         mutant tumors and any primary tumor site, we also suggest the addition of bevacizumab rather an EGFR inhibitor to chemotherapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Patients who are ineligible for bevacizumab may be offered chemotherapy alone. EGFR inhibitors are not used in patients with
         <em>
          RAS
         </em>
         or
         <em>
          BRAF
         </em>
         mutant tumors due to disease resistance. (See
         <a class="local">
          'RAS or BRAF mutant tumors'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'RAS'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15802.html" rel="external">
          "Systemic therapy for metastatic colorectal cancer: General principles", section on 'BRAF mutations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients who are not candidates for intensive therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who are not candidates for an intensive first-line chemotherapy because of age, poor PS or associated comorbidity, but who are fit enough to tolerate some form of systemic therapy, options include dose-reduced FOLFOX, a fluoropyrimidine alone, or, for patients with no contraindication, a fluoropyrimidine plus
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/2512.html" rel="external">
          "Therapy for metastatic colorectal cancer in older adult patients and those with a poor performance status", section on 'Less fit patients with an ECOG PS 0 or 1'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals with a poor PS (eg, Eastern Cooperative Oncology Group [ECOG] PS ≥2  (
         <a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">
          table 11
         </a>
         )) usually tolerate chemotherapy poorly, and in most cases, supportive care should be emphasized. Specific recommendations are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/2512.html" rel="external">
          "Therapy for metastatic colorectal cancer in older adult patients and those with a poor performance status", section on 'Frail, significant functional impairment, poor performance status'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adjunctive treatment with vitamin D
         </strong>
         – Given the potential benefits of vitamin D in terms of skeletal health and the possibility of better cancer-related outcomes in patients with higher serum levels, we test serum vitamin D levels in patients with newly diagnosed mCRC, and replete those with low levels (serum 25[OH]D &lt;20 ng/mL [50 nmol/L]). (See
         <a class="local">
          'Issues related to vitamin D'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2404938220">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Axel Grothey, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Van Cutsem E, Taieb J, Yaeger R, et al. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer. J Clin Oncol 2023; 41:2628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007; 12:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Gramont A, Buyse M, Abrahantes JC, et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007; 25:3224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeoh C, Chau I, Cunningham D, et al. Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. Clin Colorectal Cancer 2003; 3:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hejna M, Kornek GV, Raderer M, et al. Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Br J Cancer 1998; 78:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Townsend AR, Bishnoi S, Broadbridge V, et al. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. Am J Clin Oncol 2013; 36:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23:9441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiorean EG, Nandakumar G, Fadelu T, et al. Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. JCO Glob Oncol 2020; 6:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27:1386.
          </a>
         </li>
         <li class="breakAll">
          NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed on October 27, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris VK, Kennedy EB, Baxter NN, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol 2023; 41:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009; 249:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cremolini C, Casagrande M, Loupakis F, et al. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. Eur J Cancer 2017; 73:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371:1609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomasello G, Petrelli F, Ghidini M, et al. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis. JAMA Oncol 2017; 3:e170278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16:1306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25:1670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masi G, Vasile E, Loupakis F, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst 2011; 103:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cremolini C, Antoniotti C, Rossini D, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020; 21:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006; 94:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurwitz HI, Tan BR, Reeves JA, et al. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). Oncologist 2019; 24:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gruenberger T, Bridgewater J, Chau I, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 2015; 26:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modest DP, Martens UM, Riera-Knorrenschild J, et al. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). J Clin Oncol 2019; 37:3401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cremolini C, Antoniotti C, Stein A, et al. Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. J Clin Oncol 2020; :JCO2001225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sastre J, Vieitez JM, Gomez-España MA, et al. Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs). J Clin Oncol 2019; 37S:ASCO #3507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geissler M, Riera-Knorrenschild J, Martens UM, et al. Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC). J Clin Oncol 2019; 37S:ASCO #3511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cremolini C, Antoniotti C, Lonardi S, et al. Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC. J Clin Oncol 2019; 37S:ASCO #3508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modest DP, Fischer von Weikersthal L, Decker T, et al. Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110). J Clin Oncol 2019; 37:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol 2011; 12:1032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin in advanced colorectal cancer (abstract). Proc Am Soc Clin Oncol 2002; 21:129a.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Köhne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23:4856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abrams TA, Meyer G, Schrag D, et al. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst 2014; 106:djt371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23:4866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamazaki K, Nagase M, Tamagawa H, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol 2016; 27:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parikh AR, Lee FC, Yau L, et al. MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer. Clin Cancer Res 2019; 25:2988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratain MJ. Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"? J Clin Oncol 2002; 20:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathijssen RH, Verweij J, de Jonge MJ, et al. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002; 20:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 2002; 38:1677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miya T, Goya T, Fujii H, et al. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. Invest New Drugs 2001; 19:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raymond E, Boige V, Faivre S, et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002; 20:4303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathijssen RH, Marsh S, Karlsson MO, et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9:3246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michael M, Thompson M, Hicks RJ, et al. Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. J Clin Oncol 2006; 24:4228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27:5727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grothey A, Hart LL, Rowland KM, et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. J Clin Oncol 2008; 26S:ASCO #4010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takimoto CH, Remick SC, Sharma S, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003; 21:2664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doroshow JH, Synold TW, Gandara D, et al. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol 2003; 30:14.
          </a>
         </li>
         <li class="breakAll">
          Green E, Sargent DJ, Goldberg RM, Grothey A. Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741 (abstract). Data presented at the 2005 ASCO Gastrointestinal Cancers Symposium, Hollywood, Florida, January 28, 2005.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Overman MJ, Maru DM, Charnsangavej C, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 2010; 28:2549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta NN, Ravikumar R, Coldham CA, et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol 2008; 34:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008; 247:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slade JH, Alattar ML, Fogelman DR, et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 2009; 8:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009; 27:3385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Overman MJ, Ferrarotto R, Raghav K, et al. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. J Natl Cancer Inst 2018; 110:888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luz JH, Luz PM, Marchiori E, et al. Partial splenic embolization to permit continuation of systemic chemotherapy. Cancer Med 2016; 5:2715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Passhak M, Shachar SS, Ofer A, Beny A. Partial splenic embolization in the treatment of prolonged thrombocytopenia due to hypersplenism in metastatic cancer patients. Support Care Cancer 2018; 26:3527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heianna J, Muto O, Miyauchi T, et al. Successful treatment continuation with a single mild partial splenic embolization for thrombocytopenia caused by oxaliplatin-based chemotherapy for advanced colon cancer. Indian J Gastroenterol 2016; 35:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beji H, De La Fouchardière C, Desseigne F, et al. Thrombocytopenia due to hypersplenism in oncological disease: partial splenic embolization during palliative treatment. Diagn Interv Imaging 2015; 96:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26:3523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Díaz-Rubio E, Tabernero J, Gómez-España A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25:4224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Cancer 2005; 104:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21:1307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26:2006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porschen R, Arkenau HT, Kubicka S, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25:4217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ducreux M, Bennouna J, Hebbar M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 2011; 128:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo Y, Xiong BH, Zhang T, et al. XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis. Cancer Invest 2016; 34:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassidy J, Clarke S, Díaz-Rubio E, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011; 105:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26:2118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25:4779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Souglakos J, Ziras N, Kakolyris S, et al. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). Br J Cancer 2012; 106:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pectasides D, Papaxoinis G, Kalogeras KT, et al. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer 2012; 12:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skof E, Rebersek M, Hlebanja Z, Ocvirk J. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer 2009; 9:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ducreux M, Adenis A, Pignon JP, et al. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Eur J Cancer 2013; 49:1236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Köhne CH, De Greve J, Hartmann JT, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008; 19:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guo Y, Shi M, Shen X, et al. Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis. Clin Colorectal Cancer 2014; 13:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayer RJ. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 2007; 25:4165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu RH, Muro K, Morita S, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hong YS, Park YS, Lim HY, et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol 2012; 13:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada Y, Takahari D, Matsumoto H, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 2013; 14:1278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopec JA, Yothers G, Ganz PA, et al. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. J Clin Oncol 2007; 25:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennouna J, Saunders M, Douillard JY. The role of UFT in metastatic colorectal cancer. Oncology 2009; 76:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douillard JY, Zemelka T, Fountzilas G, et al. FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study. Clin Colorectal Cancer 2014; 13:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheikh HY, Valle JW, Waddell T, et al. Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. Br J Cancer 2008; 99:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bajetta E, Di Bartolomeo M, Buzzoni R, et al. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Br J Cancer 2007; 96:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shigeta K, Hasegawa H, Okabayashi K, et al. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer. Int J Cancer 2016; 139:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008; 26:5721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer von Weikersthal L, Schalhorn A, Stauch M, et al. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. Eur J Cancer 2011; 47:206.
          </a>
         </li>
         <li class="breakAll">
          ZIRABEV (bevacizumab-bvzr) injection, for intravenous use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761099s000lbl.pdf (Accessed on July 09, 2019).
         </li>
         <li class="breakAll">
          MVASI (bevacizumab-awwb) Solution for intravenous infusion. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761028s000lbl.pdf (Accessed on July 09, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurwitz HI, Tebbutt NC, Kabbinavar F, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013; 18:1004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang W, Ren L, Liu T, et al. Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial. J Clin Oncol 2020; 38:3175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008; 26:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stathopoulos GP, Batziou C, Trafalis D, et al. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology 2010; 78:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Passardi A, Nanni O, Tassinari D, et al. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol 2015; 26:1201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011; 305:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29:2011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berlin J, Posey J, Tchekmedyian S, et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007; 6:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Köhne CH, Hofheinz R, Mineur L, et al. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol 2012; 138:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22:1535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qin S, Li J, Wang L, et al. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial. J Clin Oncol 2018; 36:3031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377:2103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tveit KM, Guren T, Glimelius B, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30:1755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014; 15:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bridgewater JA, Pugh SA, Maishman T, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2020; 21:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28:4697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014; 25:1346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cremolini C, Antoniotti C, Lonardi S, et al. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. JAMA Oncol 2018; 4:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu H, Wang K, Huang M, et al. Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial. Oncologist 2021; 26:e90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossini D, Antoniotti C, Lonardi S, et al. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. J Clin Oncol 2022; 40:2878.
          </a>
         </li>
         <li class="breakAll">
          Van Cutsem E, Humblet Y, Gelderblom H, et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer aith no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetics and efficacy data of a randomized study (abstract). Data presented at the 4th annual ASCO Gastrointestinal Cancers Symposium, Orlando, FL, January 20, 2007.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peeters M, Siena S, Van Cutsem E, et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer 2009; 115:1544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berlin J, Van Cutsem E, Peeters M, et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): pooled analysis of five clinical trials (abstract). J Clin Oncol 2007; 25S: ASCO #4134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holch JW, Held S, Stintzing S, et al. Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306). Ann Oncol 2020; 31:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Cutsem E, Tejpar S, Vanbeckevoort D, et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 2012; 30:2861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ensslin CJ, Rosen AC, Wu S, Lacouture ME. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol 2013; 69:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005; 97:1221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007; 8:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stintzing S, Fischhaber D, Mook C, et al. Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels. Anticancer Drugs 2013; 24:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao Y, Liu L, Liao C, et al. Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer. Cancer Chemother Pharmacol 2010; 66:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stintzing S, Modest DP, Rossius L, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 2016; 17:1426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA 2017; 317:2392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 2016; 34S:ASCO #3504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holch JW, Ricard I, Stintzing S, et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur J Cancer 2017; 70:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rivera F, Karthaus M, Hecht JR, et al. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis 2017; 32:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yin J, Cohen R, Jin Z, et al. Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. J Natl Cancer Inst 2021; 113:1705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossini D, Boccaccino A, Carullo M, et al. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials. Eur J Cancer 2023; 184:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loree JM, Pereira AAL, Lam M, et al. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res 2018; 24:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe J, Muro K, Shitara K, et al. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA 2023; 329:1271.
          </a>
         </li>
         <li class="breakAll">
          Yoshino T, Watanabe J, Shitara K, et al. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial (abstract LBA1).  J Clin Oncol 40, 2022 ()suppl 17;abstrLBA1). Abstract available online at https://meetings.asco.org/2022-asco-annual-meeting/14416?presentation=208990#208990 (Accessed on June 09, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinelli E, Cremolini C, Mazard T, et al. Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study. ESMO Open 2022; 7:100603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stintzing S, Heinrich K, Tougeron D. Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116). J Clin Oncol 2021; 39;15S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannakis M, Mu XJ, Shukla SA, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep 2016; 17:1206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antoniotti C, Rossini D, Pietrantonio F, et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 2022; 23:876.
          </a>
         </li>
         <li class="breakAll">
          Lenz H-J, Parikh AR, Spigel DR, et al. Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8 (abstract). J Clin Oncol 40:4_suppl,8-8. Abstract available online at https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.008 (Accessed on June 09, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tian J, Chen JH, Chao SX, et al. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nat Med 2023; 29:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonbol MB, Mountjoy LJ, Firwana B, et al. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. JAMA Oncol 2020; 6:e194489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           André T, Shiu KK, Kim TW, et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med 2020; 383:2207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andre T, Amonkar M, Norquist JM, et al. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 2022; 23:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colle R, Radzik A, Cohen R, et al. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Eur J Cancer 2021; 144:9.
          </a>
         </li>
         <li class="breakAll">
          FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-line-immunotherapy-patients-msi-hdmmr-metastatic-colorectal-cancer (Accessed on July 02, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lenz HJ, Van Cutsem E, Luisa Limon M, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol 2022; 40:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng K, Meyerhardt JA, Wu K, et al. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol 2008; 26:2984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaughan-Shaw PG, Zgaga L, Ooi LY, et al. Low plasma vitamin D is associated with adverse colorectal cancer survival after surgical resection, independent of systemic inflammatory response. Gut 2020; 69:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuan C, Sato K, Hollis BW, et al. Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Clin Cancer Res 2019; 25:7497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng K, Nimeiri HS, McCleary NJ, et al. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. JAMA 2019; 321:1370.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2503 Version 136.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36763936" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17227899" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The continuum of care: a paradigm for the management of metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17664470" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12952566" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9743296" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22270106" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15051767" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16361649" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32150483" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27380959" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27380959" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36252154" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Treatment of Metastatic Colorectal Cancer: ASCO Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19247029" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27986363" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25337750" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28542671" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26338525" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17470860" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21123833" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32164906" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16508637" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30552157" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25538173" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31609637" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32816630" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with≥3 baseline circulating tumor cells (bCTCs)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17630037" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17630036" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30388045" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21903473" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10944126" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin in advanced colorectal cancer (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10623704" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10744089" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11006366" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15939923" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14665611" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24511107" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14657227" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15939922" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27177863" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30224341" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11773147" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11773157" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12175683" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Dosing strategies for anticancer drugs: the good, the bad and body-surface area.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11291833" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12409328" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12960109" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Irinotecan pathway genotype analysis to predict pharmacokinetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16896007" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19786657" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12860942" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14523790" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14523790" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20406923" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18160247" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18156931" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16648507" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19822514" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19414665" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29346573" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27611010" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Partial splenic embolization to permit continuation of systemic chemotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29696427" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Partial splenic embolization in the treatment of prolonged thrombocytopenia due to hypersplenism in metastatic cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27230031" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Successful treatment continuation with a single mild partial splenic embolization for thrombocytopenia caused by oxaliplatin-based chemotherapy for advanced colon cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25737395" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Thrombocytopenia due to hypersplenism in oncological disease: partial splenic embolization during palliative treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18640933" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17548839" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15948167" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12663719" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18421053" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17548840" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20473862" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26864862" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21673685" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18445840" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Potential regional differences for the tolerability profiles of fluoropyrimidines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17947725" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22240792" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22748098" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19386096" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23352604" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18065406" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24461997" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17709796" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29555258" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23062232" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24225157" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17264338" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19299903" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : The role of UFT in metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24370353" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18682717" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17245343" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27061810" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19001325" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20971632" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20971632" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20971632" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15175435" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23881988" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17442997" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18421054" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32749938" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18235136" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20798560" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Treatment of colorectal cancer with and without bevacizumab: a phase III study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25735317" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12506171" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21285426" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16118771" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17686822" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19339720" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21502544" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17531105" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21960318" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21228335" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30199311" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21641636" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22473155" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24717919" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32014119" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20921465" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24718886" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24024839" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19942479" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29450468" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33400355" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35666229" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35666229" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19189371" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): pooled analysis of five clinical trials (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31912799" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22753904" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23981682" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16106027" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Cetuximab therapy and symptomatic hypomagnesemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17466895" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23863616" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19760217" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Meta-analysis of incidence and risk of hypokalemia with cetuximab-based therapy for advanced cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27575024" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27722750" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28632865" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27907852" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28424871" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34061178" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36913832" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29180604" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37071094" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37071094" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36368253" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19114685" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19196673" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27760322" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23890059" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Oncology meets immunology: the cancer-immunity cycle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35636444" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35636444" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36702949" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31855256" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33264544" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33812497" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35427471" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33316636" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33316636" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34637336" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18565885" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31023832" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Low plasma vitamin D is associated with adverse colorectal cancer survival after surgical resection, independent of systemic inflammatory response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31548349" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30964527" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
